72nd
ANNUAL CONVENTION

THEME
"Welcome Back"

SOUVENIR PROGRAMME

APRIL 20-22, 2023
SHANGRI-LA THE FORT
# TABLE OF CONTENTS

2 Messages

<table>
<thead>
<tr>
<th>Schedule of Sessions</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 Day 1</td>
</tr>
<tr>
<td>4 Day 2</td>
</tr>
<tr>
<td>5 Day 3</td>
</tr>
</tbody>
</table>

6 Speakers

18 Opening Ceremonies

19 Fellowship Night Programme

20 Closing Ceremonies

21 New Diplomates

24 Anatomic Pathology

24 Clinical Pathology

30 Anatomic and Clinical Pathology

33 New Fellows

34 Anatomic Pathology

35 Clinical Pathology

35 Anatomic and Clinical Pathology

37 New Subspecialists

38 Awardees

PSP 72nd Annual Convention Research Competition

43 Guidelines / Rules

47 List of Judges

48 Oral Presentations – Finalists

54 Poster Presentations – Finalists

71 PSP Vision & Mission

72 PSP Code of Ethics

73 PSP Board of Governors

75 PSP Board of Pathology

76 PSP Regional Chapters

77 PSP Secretariat

78 PSP List of Accredited Institutions

81 Our Sponsors

114 PSP 72nd Annual Convention Organizing Committee

115 PSP Hymn
"Welcome Back" is indeed an apt theme for this year’s annual convention. It is a wonderful opportunity to be able to be with friends again, listen to the scientific lectures in-person and attend the fellowship night to enjoy and experience the camaraderie of colleagues in the profession.

I am grateful to this year’s organizing committee, led by its chair, Dr. Jeffrey S. So for painstakingly mounting the three-day event. It is never an easy task to assemble the annual convention with almost a thousand members to accommodate.

We are honored by the presence of Dr. Maria Rosario S. Vergeire, Officer in Charge and Undersecretary of the Department of Health as our keynote speaker and Dr. Maria Minerva P. Calimag, President of the Philippine Medical Association who will induct the officers and board members of the society.

The scientific lectures will be presented by both international and local speakers. The annual convention is an appropriate platform for our young Pathologists to share their experience and knowledge learned from fellowship training abroad. It is also a venue to introduce or re-introduce them to the society so we know whom to refer to our difficult and challenging cases.

Research is given an added importance this year. The junior members were encouraged to submit their research papers for platform and poster presentations. Exciting cash prizes and a specially-designed trophy await the winners.

The fellowship night committee has also produced a program that will surely entertain the members. I encourage everyone to come and join this festive celebration. It will be a great time to reconnect with colleagues whom we have not seen in the last three years. Let us take a break from our busy schedule and enjoy the night away.

I hope we all learn a thing or two from the scientific sessions during the convention. It is an occasion to talk and interact with the speakers. It will be an opportune moment to seek answers to questions that linger in the back of our mind.

I am delighted to see everyone in-person again since 2020. I welcome you to the 72nd Annual Convention of the Philippine Society of Pathologists!

Alan T. Koa, MD, FPSP
PSP President, 2022-2023
Welcome and good day everyone!

It is my privilege to welcome each one of you to our first face to face annual convention in three years.

The pandemic has brought us a multitude of challenges in our daily lives, as well as in our work as pathologists. That is why the board of governors as well as the organizing committee wanted to keep the theme of this annual convention simple and focused, yet as meaningful as possible. We just all wanted to welcome everybody back. To be happy seeing each other again, and to enjoy each other’s company.

We are also elated to welcome our esteemed international speakers, most especially my mentor, Dr. Jonathan I. Epstein. Another highlight I am excited about, is the oral presentation for the research contest will now be part of the plenary sessions. This was a very tough task, yet something I feel will be worth it in the long run. This is the one the most important avenues that we can improve as an academic society. Research has to be a focus for us, not just a small part of the program or just a requirement to finish residency.

Once again, thank you so much to the board of governors, the organizing committee, but more especially to each of you for supporting this annual convention.

Jeffrey S. So, MD, FPSP

PSP Secretary, 2022-2023
Over-All Chair, 72nd Annual Convention
## SCHEDULE OF SESSIONS

### Day 1 • 20 April 2023

<table>
<thead>
<tr>
<th>TIME</th>
<th>ACTIVITY</th>
<th>SPEAKER</th>
<th>MODERATOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 12:00 NN</td>
<td>Opening Ceremonies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 - 1:00 PM</td>
<td>LUNCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 - 1:45 PM</td>
<td>Updates and Issues on Endometrial and Endocervical Carcinomas</td>
<td>Claire Anne Therese Hemedez, MD, DPSP</td>
<td>Dr. Ma. Margot Flor S. Yasay</td>
</tr>
<tr>
<td>1:45 - 2:45 PM</td>
<td>Updates in Breast Pathology: The 2019 WHO Classification of Tumors</td>
<td>Luis Z. Blanco Jr., MD</td>
<td></td>
</tr>
<tr>
<td>2:45 - 3:00 PM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 - 4:00 PM</td>
<td>Updates in Pregnancy Associated Breast Cancer</td>
<td>Luis Z. Blanco Jr., MD</td>
<td>Dr. Kristine Joy A. Gacutno</td>
</tr>
<tr>
<td>4:00 - 4:45 PM</td>
<td>A Survey of Common Diagnostic Challenges in Dermatopathology</td>
<td>Joaquin Antonio S. Patag, MD, DPSP</td>
<td></td>
</tr>
<tr>
<td>4:45 - 5:30 PM</td>
<td>What’s New in Urinary Tract Pathology, WHO 5th Edition 2022</td>
<td>Maria Sarah L. Lenon, MD, FPSP</td>
<td></td>
</tr>
</tbody>
</table>

### Day 2 • 21 April 2023

<table>
<thead>
<tr>
<th>TIME</th>
<th>ACTIVITY</th>
<th>SPEAKER</th>
<th>MODERATOR</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 9:00 AM</td>
<td>Prostate Cancer Grading from Gleason to a Contemporary New Patient-Centric Grading System</td>
<td>Jonathan I. Epstein, MD</td>
<td>Dr. Christopher Alec A. Maquiling</td>
</tr>
<tr>
<td>9:00 - 10:00 AM</td>
<td>Prostate Pitfalls and Pearls</td>
<td>Fiona Maclean, MD</td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:45 AM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 - 11:15 AM</td>
<td>Lions and Tigers and Bears, Oh My! Myoid Tumours</td>
<td>Fiona Maclean, MD</td>
<td>Dr. Randell S. Arias</td>
</tr>
<tr>
<td>11:15 - 12:00 NN</td>
<td>Establishing the diagnosis of lymphoproliferative neoplasms and WHO 5th edition Updates</td>
<td>Rose Lou Marie C. Agbay, MD, FPSP</td>
<td></td>
</tr>
<tr>
<td>12:00 - 1:00 PM</td>
<td>LUNCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 - 2:30 PM</td>
<td>RESEARCH FORUM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30 - 3:00 PM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 - 6:00 PM</td>
<td>BUSINESS MEETING</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 PM</td>
<td>FELLOWSHIP NIGHT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIME</td>
<td>ACTIVITY</td>
<td>SPEAKER</td>
<td>MODERATOR</td>
</tr>
<tr>
<td>--------------</td>
<td>---------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>8:00 - 8:45 AM</td>
<td>The Role of the Histocompatibility Laboratory in Solid Organ Transplantation</td>
<td>Emilio Q. Villanueva III, MD, MSc, DPSP</td>
<td>Dr. Marvin C. Masalunga</td>
</tr>
<tr>
<td>8:45 - 9:30 AM</td>
<td>The ABCDs of HLA</td>
<td>Raymund Inocencio, MD, FPSP</td>
<td></td>
</tr>
<tr>
<td>9:30 - 9:45 AM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 - 10:30 AM</td>
<td>Recent Advances in Lipid-related Cardiovascular Biomarker Testing</td>
<td>Alan Thomas Remaley, MD, PhD</td>
<td>Dr. Redante D. Mendoza</td>
</tr>
<tr>
<td>10:30 - 11:15 AM</td>
<td>Triglyceride-rich Lipoproteins: From Metabolism to New Therapies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 - 12:00 NN</td>
<td>Diagnostic Testing in Tuberculosis</td>
<td>Ruby O. Rusia-Uy, MD, FPSP</td>
<td></td>
</tr>
<tr>
<td>12:00 - 1:00 PM</td>
<td>LUNCH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 - 1:45 PM</td>
<td>Contract Negotiations</td>
<td>Atty. Clarence Jandoc</td>
<td>Dr. Gerald V. Tejada</td>
</tr>
<tr>
<td>1:45 - 2:30 PM</td>
<td>Approach to the Diagnosis of Autoimmune Diseases</td>
<td>Lara Mae B. Academia-Angeles, MD, FPSP</td>
<td></td>
</tr>
<tr>
<td>2:30 - 3:30 PM</td>
<td>DOH HOUR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30 - 3:45 PM</td>
<td>BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:45 - 5:00 PM</td>
<td>CLOSING CEREMONIES</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The previous classification of endometrial and endocervical adenocarcinomas are largely based on clinical and histomorphologic features. Certain molecular updates have ushered a new classification for these diagnostic entities - TCGA molecular classification for endometrial carcinomas and the IECC for endocervical adenocarcinomas. Studies have shown that immunohistochemical stains can serve as surrogates for molecular grouping or classification.
The 2nd volume of the 5th series of the World Health Organization (WHO) tumor classifications for breast tumors was published in late 2019 and serves as the definitive resource for tumor classification worldwide, as well as an essential tool for standardizing diagnostic practice. Significant updates in this most current edition include a more standardized approach to tumors arranged from benign to malignant. In addition, evaluation of mitotic activity is now based on counts in a defined area in mm$^2$. The emerging importance of tumor infiltrating lymphocytes is addressed and a guide for quantification is illustrated. Further, very rare tumors that were previously considered distinct special subtypes have now been reclassified to the invasive carcinoma of no special type group. Similarly, tumors with medullary features are now classified as invasive carcinoma of no special type with medullary pattern. The term neuroendocrine neoplasm is now used to encompass all tumors with predominant neuroendocrine differentiation, as defined by histological features similar to small cell or large cell carcinoma of the lung and diffuse uniform immunoreactivity for neuroendocrine markers. The pathogenesis of breast fibroepithelial tumors has been further elucidate, with fibroadenomas harboring $MED12$ mutations, while phyllodes tumors have $TERT$ promoter mutations. Also, the presence of a component that resembles well differentiated liposarcoma in a phyllodes tumor is no longer sufficient as a sole criterion to warrant malignant grading. This volume also introduces two new entities in breast pathology: (1) mucinous cystadenocarcinoma (invasive breast carcinoma resembling pancreatobiliary or ovarian mucinous cystadenocarcinoma that usually has a good prognosis) and (2) tall cell carcinoma with reversed polarity (very rare variant with overlapping features between solid papillary carcinoma, papillary ductal carcinoma and invasive papillary carcinoma that is low grade and has a favorable prognosis). Finally, the 2019 WHO Classification of Breast Tumors is now available online for easier and more accessible use.
Pregnancy associated breast cancer (PABC) is breast cancer that is diagnosed during or after a recent pregnancy, commonly to within one to five years postpartum in a majority of the published literature. PABC presents in younger women as a palpable breast mass that is usually at advanced stages, with larger, higher grade, hormone receptor-negative, triple negative, or HER2-positive tumors. Although it may be of any subtype, PABC, most commonly invasive ductal carcinoma of no special type, with lymph-vascular space invasion and lymph node involvement at the time of presentation. Physiologically, pregnancy actually confers a dual effect, with an initial transient increase risk for breast cancer followed by long term protection over time. Further, the involution hypothesis posits that tissue remodeling programs that are employed during mammary gland involution are similar to wound healing and inflammation and may facilitate tumor progression and metastasis. PABC has a worse prognosis compared with age- and stage-matched non-PABC, and those diagnosed in the immediate post-partum period have a higher likelihood of metastasis and an even poorer prognosis. In addition to the inflammatory-like microenvironment of involution, PABC has been found to have a genetic signature that is associated with increased hormone-regulated cell cycling and immune response. Overall, these may play an important role in tumor progression and metastasis in PABC and contribute to the aggressive nature of this group of tumors. More recent work has found that PABC is composed of two distinct groups: (1) breast cancer occurring during pregnancy (PrBC) which has equivalent behavior to non-PABC, and (2) breast cancer occurring in the post-partum period extending to 5-10 years after birth (PPBC) which demonstrates the worse outcome. As such, the current recommendation is to no longer use PABC terminology and to separately investigate PrBC and PPBC in order to truly understand these groups and to develop the most effective targeted therapy for the appropriate patients.
Three main areas in neoplastic dermatopathology which a general pathologist must be familiar with are cutaneous carcinomas, squamoproliferative neoplasms and common spindle cell tumors. Poorly-differentiated basal cell carcinomas, sebaceous carcinomas, hidradenocarcinomas, Merkel cell carcinomas, and metastatic carcinomas, usually pose diagnostic difficulties, but a thorough examination at low, intermediate and high power objectives reveals features that suggest the correct diagnosis. Immunohistochemistry for these lesions is helpful in difficult cases. Among squamoproliferative lesions, an important diagnostic dilemma is deciding whether a squamoproliferative lesion is benign or malignant. Clinical and histologic context are important for the distinction of pseudoepitheliomatous hyperplasia from squamous cell carcinoma. There are numerous spindle cell tumors, but the prototypes from the fibrohistiocytic, myofibroblastic, nerve sheath and smooth muscle tumors are must-knows. These entities have unique characteristics allowing their differentiation and guiding the panel of immunostains to be used to confirm the diagnosis.
Histologic characteristics remain as the gold standard for the classification and diagnosis of urothelial tract tumors. As an adjunct to histology, a growing body of literature on the comprehensive molecular classification of urothelial tumors has evolved in terms of the mutation landscape, transcriptomic and proteomic signatures that provide better classification, prognosis, and selection of therapeutic targets. In addition, issues on risk stratification and pathologic sub-staging in bladder cancer exist that should be revisited due to their implications on treatment and prognosis. Urine cytology is likewise an important management tool for patients with bladder cancer. The use of Paris System (2.0) for cytologic diagnosis has been widely adopted and its use is being promulgated by this latest WHO edition as it is helpful in clinical management with its focus on detection of high-grade cytology. The Paris System is deemed to be well-suited to accurate diagnoses and clinical relevance.
Jonathan I. Epstein, MD

Professor, Departments of Pathology, Urology, & Oncology, The Reinhard Professor of Urologic Pathology, The Johns Hopkins University School of Medicine
Director of Surgical Pathology, Department of Pathology, The Johns Hopkins Hospital
Pathologist, Active Staff, Department of Pathology, The Johns Hopkins Hospital

PROSTATE CANCER GRADING FROM GLEASON TO A CONTEMPORARY NEW PATIENT-CENTRIC GRADING SYSTEM

Day 2 • 21 April 2023 • 8:00 - 9:00 AM

Fiona Maclean, MD

Senior Histopathologist, Douglass Hanly Moir (DHM) Pathology, Macquarie Park, Australia
Medical Director, St. Leonard’s Laboratory
President, Australasian Division of the International Academy of Pathology (IAP)
Clinical Associate Professor, Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University
Examiner in Anatomical Pathology, Royal College of Pathologists of Australasia (RCPA)

PROSTATE PITFALLS AND PEARLS

Day 2 • 21 April 2023 • 9:00 - 10:00 AM

LIONS AND TIGERS AND BEARS, OH MY! MYOID TUMOURS

Day 2 • 21 April 2023 • 10:15 - 11:15 AM
Morphologic examination of biopsies from nodal or extranodal sites along with the utility of immunophenotypic, molecular and cytogenetic studies provide useful data for establishing the diagnosis of lymphoproliferative neoplasms.

**ESTABLISHING THE DIAGNOSIS OF LYMPHOPROLIFERATIVE NEOPLASMS AND WHO 5TH EDITION UPDATES**

Morphologic examination of biopsies from nodal or extranodal sites along with the utility of immunophenotypic, molecular and cytogenetic studies provide useful data for establishing the diagnosis of lymphoproliferative neoplasms.
Transplantation is widely performed to replace nonfunctioning organs and tissues with healthy organs or tissues. It is done by the process of taking cells, tissues, or organs, called a graft, from one individual, called a donor, and placing them into a [usually] different individual, called a host or recipient.

Aside from the technical challenge of transplantation in surgically transplanting organs, the immune response of the host against the transplanted tissues or organs is the other major barrier to survival of the graft. In general, graft rejection is the immune response of the host to the graft due to presence of non-self human leukocyte antigen (HLA) molecules in the transplanted tissues or organs. Controlling this immune response is key to successful transplantation.

Therefore, it is the responsibility of the histocompatibility laboratory to provide a quality assured evaluation of donor-recipient histocompatibility and patient immunologic risk factors that will allow the clinician and the patient to decide which approaches to solid organ transplantation are for the patient’s best interest.
The discovery of Human Leukocyte Antigen (HLA) revolutionized the art and science of medicine particularly in the field of immunology, transplantation and infectious disease. The human leukocyte antigen (HLA) system or complex is a complex of genes on chromosome 6 in humans which encode cell-surface proteins responsible for regulation of the immune system. The HLA system is also known as the human version of the major histocompatibility complex (MHC) found in many animals. The presentation aims to introduce the basic concepts and history of clinical histocompatibility and introduce various testing methods that are currently available. The importance of the HLA system and HLA nomenclature as well as introduction to HLA antibody testing will also be included.
Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) risk is a major first step in the clinical management of patients for reducing cardiovascular disease. Given the strong association of plasma lipids with ASCVD risk, the clinical laboratory measurement of plasma lipids and lipoprotein-related parameters is important element is ASCVD risk assessment. In this lecture, lipid and lipoprotein-related diagnostic testing will be reviewed and how this information is integrated into the clinical management of patients.

Both the current routine diagnostic lipid-related tests will be discussed, plus emerging new diagnostic tests for ASCVD risk will be covered.

**RECENT ADVANCES IN LIPID-RELATED CARDIOVASCULAR BIOMARKER TESTING**

Assessment of Atherosclerotic Cardiovascular Disease (ASCVD) risk is a major first step in the clinical management of patients for reducing cardiovascular disease. Given the strong association of plasma lipids with ASCVD risk, the clinical laboratory measurement of plasma lipids and lipoprotein-related parameters is important element is ASCVD risk assessment. In this lecture, lipid and lipoprotein-related diagnostic testing will be reviewed and how this information is integrated into the clinical management of patients. Both the current routine diagnostic lipid-related tests will be discussed, plus emerging new diagnostic tests for ASCVD risk will be covered.

**TRIGLYCERIDE-RICH LIPOPROTEINS: FROM METABOLISM TO NEW THERAPIES**

Although cholesterol-rich lipoproteins like Low-Density Lipoproteins (LDL) play a causal role in the development of Atherosclerotic Cardiovascular Disease (ASCVD), many patients treated to lower LDL-C still go on to develop clinical events. This so-called residual risk has recently been proposed to be, at least in part, related to elevated Triglyceride-rich lipoproteins (TRL). In this lecture, we will review the latest findings on triglyceride and TRL metabolism and how it may contribute to the pathogenesis of ASCVD and also acute pancreatitis. Next, new therapies that specifically target TRL metabolism will be reviewed along with their impact on health outcomes.
Tuberculosis is the 13th leading cause of death and the second leading infectious killer after COVID-19, affecting both the adult and pediatric population. Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs but also cause extrapulmonary disease. TB is spread from person to person through the air. When people with lung TB cough, sneeze or spit, they propel the TB germs into the air. A person needs to inhale only a few of these germs to become infected. Tuberculosis is curable and preventable. However, the emergence of multidrug-resistant tuberculosis (MDR-TB) remains a public health crisis and a health security threat.

The highest priority in any TB control program is the prompt detection of cases and the provision of chemotherapy to all patients under proper case-management conditions. The World Health Organization’s End TB Strategy target of “No TB patients and their households facing catastrophic costs as a result of TB disease” was adopted in 2015. One of its pillars incorporates all technological innovations such as early diagnostic approaches.
Autoimmune disorders remain to be a challenge when it comes to diagnosis since they mimic many other disorders. Many autoimmune disorders involve several organ systems so careful evaluation along with clinical data may help the clinicians in the diagnostic approach to these diseases. As pathologists, it is our goal to aid in the diagnostic arm of the disease with the use of appropriate laboratory tests such as immunofluorescence. Immunofluorescence assays have been one of the mainstays in the initial workup of autoimmune diseases. Our role is to be able to identify the basic patterns using the latest ICAP Patterns Classification in the screening of autoimmune diseases. This lecture aims to update us in the recognition of basic patterns in immunofluorescence technology and its practical use in the approach to autoimmune disorders.
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 12:00</td>
<td>Processional – New Diplomates, Awardees, PRO President, Organizing Committee, Board of Pathology, Regional Chapter Presidents, Intro keynote, Board of Governors, Annual Convention Chair, PSP President and Keynote Speaker</td>
</tr>
<tr>
<td></td>
<td>Entrance of Colors</td>
</tr>
<tr>
<td></td>
<td>Invocation AVP</td>
</tr>
<tr>
<td></td>
<td>The Philippine National Anthem AVP</td>
</tr>
<tr>
<td></td>
<td>PMA Hymn AVP</td>
</tr>
<tr>
<td></td>
<td>PSP Hymn PSP Family</td>
</tr>
<tr>
<td>8:45 AM</td>
<td>Welcome Remarks</td>
</tr>
<tr>
<td></td>
<td>Opening Remarks</td>
</tr>
<tr>
<td></td>
<td>Acknowledgment of Past Presidents</td>
</tr>
<tr>
<td></td>
<td>Introduction to Keynote Speaker</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Keynote Address</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Presentation of New Diplomates</td>
</tr>
<tr>
<td></td>
<td>Oath of Office of New Diplomates</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Awarding Ceremonies</td>
</tr>
<tr>
<td></td>
<td>Dr. Benjamin A. Barrera Service Award <em>(Posthumous)</em></td>
</tr>
<tr>
<td></td>
<td>Outstanding Pathologist Award</td>
</tr>
<tr>
<td></td>
<td>Distinguished Service Award</td>
</tr>
<tr>
<td></td>
<td>Dr. Liborio Gomez Memorial Award and Lecture</td>
</tr>
<tr>
<td>12:00 NN</td>
<td>Singing of the PSP Hymn</td>
</tr>
</tbody>
</table>

**OPENING CEREMONIES**

**Day 1 • 20 April 2023**

**8:00 - 12:00 NN**
- Processional – New Diplomates, Awardees, PRO President, Organizing Committee, Board of Pathology, Regional Chapter Presidents, Intro keynote, Board of Governors, Annual Convention Chair, PSP President and Keynote Speaker
- Entrance of Colors
- Invocation
- The Philippine National Anthem
- PMA Hymn
- PSP Hymn

**8:45 AM**
- Welcome Remarks
- Opening Remarks
- Acknowledgment of Past Presidents
- Introduction to Keynote Speaker

**9:00 AM**
- Keynote Address

**9:30 AM**
- Presentation of New Diplomates
- Oath of Office of New Diplomates

**10:30 AM**
- Awarding Ceremonies
- Dr. Benjamin A. Barrera Service Award *(Posthumous)*
- Outstanding Pathologist Award
- Distinguished Service Award
- Dr. Liborio Gomez Memorial Award and Lecture

**12:00 NN**
- Singing of the PSP Hymn
Day 2 • 21 April 2023

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Performer</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 PM</td>
<td>Opening and Welcome Remarks, Dinner and Drinks, Raffle</td>
<td></td>
</tr>
<tr>
<td>9:00 PM</td>
<td>Live Music Performance</td>
<td>Gigi De Lana and the Gigi Vibes Band</td>
</tr>
<tr>
<td>10:30 PM</td>
<td>Raffle, Party and Music</td>
<td></td>
</tr>
</tbody>
</table>

Attire: Semiformal / Smart Casual

Serren Lor V. Gallinero, MD, DPSP  
Master of Ceremony

Francis G. Moria, MD, FPSP  
Head, Committee on Fellowship Night
## CLOSING CEREMONIES

### Day 3 • 22 April 2023

<table>
<thead>
<tr>
<th>Description</th>
<th>Name(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Invocation</td>
<td></td>
</tr>
<tr>
<td>The Philippine National Anthem</td>
<td></td>
</tr>
<tr>
<td>PMA Hymn</td>
<td>AVP</td>
</tr>
</tbody>
</table>
| Opening Remarks                                                             | Jeffrey S. So, MD, FPSP
  Secretary & Over-All Chair, 72<sup>nd</sup> Annual Convention           |
| Introduction of Guest Speaker                                              |                                                                        |
| Short Message                                                               | Ma. Minerva P. Calimag
  President, Philippine Medical Association                                   |
| Recognition of Fellows                                                       | PSP President with Chair, Committee on Membership                      |
| Oath of Fellows                                                              |                                                                        |
| Recognition of Sub-specialists                                              |                                                                        |
| Oath of Sub-specialists                                                      |                                                                        |
| Valedictory Address                                                         | Alan T. Koa, MD, FPSP
  President, PSP                                                               |
| Turnover Ceremonies                                                         | Ma. Minerva P. Calimag
  President, Philippine Medical Association                                   |
| Induction of Executive Officers and Members of the Board of Governors       |                                                                        |
| Acceptance Speech                                                           | Incoming PSP President                                                 |
| Induction of New Officers                                                    |                                                                        |
| Regional Chapter Presidents                                                 |                                                                        |
| PSP Circle Officers                                                         |                                                                        |
| Pathology Residents’ Organization                                           |                                                                        |
| Recognition of 72<sup>nd</sup> Annual Convention Organizing Committee       | Jeffrey S. So, MD, FPSP
  Over-All Chair, 72<sup>nd</sup> Annual Convention                         |
| Sponsors                                                                     |                                                                        |
| Awarding of Prizes                                                          | Amado Tandoc III, MD, FPSP and
  Justine Alessandra U. Uy, MD, FPSP                                         |
| Oral Presentations                                                          | Chair, Committee on Research                                           |
| Poster Presentations                                                        |                                                                        |
| Presentation of Certificates to Training Institutions                       | Ma. Yvonette C. Nerves, MD, FPSP
  Chair, Accreditation of Pathology Training Program                         |
| Closing Remarks                                                             | Maria Cecilia F. Lim, MD, FPSP
  Co-Chair, 72<sup>nd</sup> Annual Convention                               |
| PSP Hymn                                                                    | PSP Family                                                             |

Mirian D. Viterbo, MD, FPSP

Chair, Closing Ceremonies
NEW DIPLOMATES – ANATOMIC PATHOLOGY 2023

Abadiano, Dino Raphael K.
Chong Hua Hospital

Apao, Carmel Therese B.
Cebu Doctors’ University Hospital

Ballacillo, Marie Anne Pauline B.
East Avenue Medical Center

Bustria, Allan Ernie C.
Baguio General Hospital
and Medical Center

Catapia, David Thomas S.
Chinese General Hospital
and Medical Center

Cruz, Victoria E.
UERM Memorial Medical Center

Cular, Cresta Anne Salve G.
Eastern Visayas Medical Center
NEW DIPLOMATES – ANATOMIC PATHOLOGY 2023

Dizon, Lea Mae Patricia L.
Jose B. Lingad Memorial General Hospital

Go, Jennifer T.
The Medical City

Guro, Rashidah A.
Northern Mindanao Medical Center

Laporga, Joahnne C.
Region 1 Medical Center

Lorenzo, Lara Mae S.
The Medical City

Medina, Jennifer Jane U.
Vicente Sotto Memorial Medical Center

Molas, Rose Franses C.
Philippine Children’s Medical Center
NEW DIPLOMATES – ANATOMIC PATHOLOGY 2023

Nuesca, Amerlito A.
Baguio General Hospital and Medical Center

Romero, Miles S.
Western Visayas Medical Center

Rosales, Carole Zaidel M.
Quirino Memorial Medical Center

Sangalang, Jose Mari Carmelo A.
The Medical City

Santos, Pocholo D.
Makati Medical Center

Sarmiento, Christian Roy Q.
Zamboanga City Medical Center

Ticse, Joed T.
Dr. Paulino J. Garcia Memorial Research and Medical Center
NEW DIPLOMATES – CLINICAL PATHOLOGY 2023

Abella, Jesser Dann Q.
West Visayas State University Medical Center

Allanique, Ma. Charissa P.
Jose R. Reyes Memorial Medical Center

Angeles, Aldred Ivan I.
Quirino Memorial Medical Center

Bagalanon, Fereylou A.
Governor Celestino Gallares Memorial Hospital

Banaag, Marianne Karen Gay B.
Makati Medical Center

Basilla, Michelle R.
Vicente Sotto Memorial Medical Center

Calupas, Laurie Marie C.
Rizal Medical Center
NEW DIPLOMATES – CLINICAL PATHOLOGY 2023

Cohitmingao Ian Joy Q.
Vicente Sotto Memorial Medical Center

De Guzman, Ma. Patricia Lourena A.
De La Salle University Medical Center

Detiquez Kathleen P.
St. Luke’s Medical Center – Quezon City

Dizon, Lea Mae Patricia L.
Jose B. Lingad Memorial General Hospital

Dugay, Anna Patricia C.
Ospital ng Maynila Medical Center

Dy, Arnel Christian K.
UERM Memorial Medical Center

Gallinero, Serren Lor V.
Western Visayas Medical Center
NEW DIPLOMATES – CLINICAL PATHOLOGY 2023

Gonzales, Arnold Paul K.
Western Visayas Medical Center

Guevarra, Jireh Joy F.
West Visayas State University Medical Center

Haron-Gangco, Harriza M.
Jose R. Reyes Memorial Medical Center

Honculada, Anne Moonyeen H.
Governor Celestino Gallares Memorial Hospital

Lim, Janelda Ann Margui S.
Valenzuela Medical Center

Mangosong, Samantha Joy M.
Tondo Medical Center

Marquez, Joanna Melissa F.
Zamboanga City Medical Center
NEW DIPLOMATES – CLINICAL PATHOLOGY 2023

Martinez, Arasse Dino G.
Jose R. Reyes Memorial Medical Center

Martinez, Maria Zelda D.
Jose R. Reyes Memorial Medical Center

Mateo, Jennifer Y.
Victoriano Luna Medical Center

Mendoza, Jesse G.
Philippine Heart Center

Miranda, Dinarazad D.
Philippine Heart Center

Misoles, Cyril Pete Martin S.
Davao Doctors Hospital

Nagtalon, Rebecca R.
St. Luke’s Medical Center – Global City

Navasquez, Warfe, C.
Cebu Doctors’ University Hospital
NEW DIPLOMATES – CLINICAL PATHOLOGY 2023

Olac Jr., Ray V.
Western Visayas State University Medical Center

Ong-Dulay, Angelica Gizelle
Ospital ng Maynila Medical Center

Planto III, Mark Anthony B.
Western Visayas Medical Center

Platon, Enrick John M.
Makati Medical Center

Quisto, Melchor N.
Western Visayas Medical Center

Reyes, Robert R.
National Kidney and Transplant Institute

Ruiz, Marjorie D.
East Avenue Medical Center
NEW DIPLOMATES – CLINICAL PATHOLOGY 2023

Soliveres, Eunice Joy I.
St. Luke’s Medical Center – Quezon City

Suico, Arantxa C.
Cebu Doctors’ University Hospital

Tamiray, Heidiliz Joy L.
Baguio General Hospital and Medical Center

Tejada, Gian Ysmael B.
Valenzuela Medical Center

Tubo, Gordon Christopher C.
Vicente Sotto Memorial Medical Center

Yarra, Erica Ayn V.
East Avenue Medical Center

Zonita, Paulyn I.
Western Visayas Medical Center
NEW DIPLOMATES – ANATOMIC AND CLINICAL PATHOLOGY 2023

Bonifacio, Kathleen M.
National Kidney and Transplant Institute

Cancio, Jonathan Emmanuel G.
University of the Philippines – Philippine General Hospital

Carrillo, Ma. Novie S.
Western Visayas State University Medical Center

Chavez, Reedan E.
Western Visayas Medical Center

Dalangin, Dulce Ann Ross B.
Batangas Medical Center

De La Cruz, Ace John Felix S.
Western Visayas Medical Center

Dela Cruz, Kamille Faye P.
Quirino Memorial Medical Center
NEW DIPLOMATES – ANATOMIC AND CLINICAL PATHOLOGY 2023

Dimacali, Liaa Marie G.
Jose B. Lingad Memorial General Hospital

Ellazar, Albert Charles V.
Quirino Memorial Medical Center

Lipayon, Kristyn J.
Eastern Visayas Medical Center

Ong, David Jerome P.
The Medical Center

Remotigue, Jose Louie D.
University of the Philippines – Philippine General Hospital

Reyes, Ralph Adrian A.
St. Luke’s Medical Center – Quezon City

Salise, Joeanne Marie M.
University of the Philippines – Philippine General Hospital
NEW DIPLOMATES –
ANATOMIC AND CLINICAL PATHOLOGY 2023

Sebastian, Franz Jobert L.
Philippine Heart Center

Tino-Banayat, Jela Patricia B.
Ospital ng Maynila Medical Center

Trespeces, John Ruvil P.
Western Visayas Medical Center

Umali, John Basil C.
Chinese General Hospital and Medical Center
NEW FELLOWS – ANATOMIC PATHOLOGY 2023

Mendoza, Jefferson B.

Tolentino-Molina, Maria Kariza L.
NEW FELLOWS – CLINICAL PATHOLOGY 2023

Haron, Iftizar N.

Koa, Warren Welby O.

Oblefias, Jonathan Z.

Rafanan, Azenith May H.

Tan, Alvin Rey B.
NEW FELLOWS –
ANATOMIC AND CLINICAL PATHOLOGY 2023

Abubakar, Al-Zamzam A.
Ang, Heidi T.
Jovida-Castro, Ma. Christina
Cerillo, Catherine M.
Crisostomo, Kenneth C.
Hernandez-Sionzon, Melani S.
Madrid-Estoesta, Cheshire Therese A.
NEW FELLOWS –
ANATOMIC AND CLINICAL PATHOLOGY 2023

Marabi, Monalyn T.

Mendoza-Leaño, Aida Isabel

Ramos, Shiela May N.

Tanawit, Gail Domecq C.

Torres, Jennifer B.

Uy, Justine Alessandra U.
NEW SUBSPECIALISTS 2023

Ang, Daphne C.
Oncologic Pathology
Molecular Pathology
Hemopathology

Dela Cruz, Rouchelle D.
Hepatopathology / Liver Pathology

Espiritu, Joseph Michael R.
Molecular Pathology

Patag, Joaquin Antonio S.
Dermatopathology
2022 BENJAMIN A. BARRERA SERVICE AWARD
(POSTHUMOUS)

Dr. Arsenio C. Cantos

In remembrance of his dedicated service as president of our society, his selfless generosity that saw to the acquisition and construction of a site and a home for the PSP, his involvement, commitment and support to the objectives, ideals and aspirations of the Society which contributed to its spirited existence and vibrant growth.
In remembrance of his dedicated service as president of our society, his tireless participation that ensured the inclusive representation of our provincial practitioners, his exemplary and unparalleled devotion and guidance to the Society which contributed to its responsive existence and dynamic growth.
2022 DISTINGUISHED SERVICE AWARD

Dr. Edna May Lasap-Go

In recognition of her notable and exemplary service to the Society through the years with consistent, active, and continuing participation in various capacities in the affairs of the Society, including promoting the interest of the Society and Pathology, and fostering local and regional linkages through involvement in national and international activities.
2022 OUTSTANDING PATHOLOGIST AWARD

Dr. Gary U. Ong

In recognition of his vibrant steerage of the blood services programs in his region, and his professional and administrative expertise acknowledged by his peers, culminating in his appointment as medical center chief, and president of the Philippine Blood Coordinating Council, substantially contributing to the promotion of the discipline and the image of the Society.
In recognition of his distinguished career as an academician and educator, his pioneering furtherance of the field of gastrointestinal pathology, and his wholehearted sharing to the Society of his knowledge and expertise – a testament to his remarkable involvement in the promotion and advancement of the science of pathology in the fields of medical education, research, and professionalism.

Dr. Andrew D. Dimacali
PSP 72nd ANNUAL CONVENTION
RESEARCH COMPETITION

General Rules and Eligibility

1. All members of the Philippine Society of Pathologists, Inc. (Junior, Diplomate, and Fellow members) are eligible to participate in the 72nd PSP Annual Convention proffered / platform formal research competition.

2. The manuscript submission period for the 72nd PSP Annual Convention is until March 27, 2023, 11:59 PM.

3. Original anatomic and/or clinical pathology articles of any study design (e.g., meta-analysis / systematic review, descriptive, analytical / inferential, experimental) may be accepted for assessment provided that prior Institutional Review Board (IRB) approval has been secured.

4. Strict adherence to the provided manuscript submission guidelines is required. See the succeeding section.

5. No limit is imposed as to the number of manuscripts a researcher may submit; however, a principal author may present only one (1) research undertaking during the event. The Philippine Society of Pathologists, Inc. reserves the right to select the paper to be presented during the forum. There are no imposed limits for co-authorship.

6. Five (5) finalists will proceed to the Oral platform presentation. Participants will be notified through email regarding the acceptance or rejection of their entries no later than April 14, 2023 (Friday). Upon acceptance for presentation, the author must immediately register for the convention if he/she has not yet done so.

7. Prior to the annual convention, the research entry must not have been published elsewhere.

Manuscript Submission Guidelines

1. All original article manuscripts must be written in the English language and must adhere to the general and specific formatting guidelines of the Philippine Journal of Pathology, available at: https://philippinejournalofpathology.org/index.php/PJP/about/submissions.

2. Manuscript PDF files (.pdf) must be submitted to PSP72ndAC.research@gmail.com with the file and email subject title being: “ORAL_(Initials)_(Title)” (ex. ORAL_AKP_Research title). Once submitted, no further changes or revisions may be executed. Anonymized copies will be forwarded for judging.

3. Please also submit a recent 2 x 2 photo with white background, filename: “ORAL_ID_(Full Name)”

4. Winning papers will be published in the Philippine Journal of Pathology following revisions based on judges’ reviews and final editing. Worthy non-winning papers may also be published in the PJP upon acceptance by the editor, subject also to revisions based on judges' reviews and final editing. Proper documentation of copyright transfer will be executed following official PJP protocol.
**Oral Research Presentation**

1. Proffered / platform research presentations are scheduled for April 21, 2023 (Day 2) from 1:30 PM to 3:00 PM at the Grand Ballroom of the Shangri-la Hotel, Fort Bonifacio, BGC, Taguig.

2. The call time for presenters set at 12:30 PM for a preliminary tech run. English is the required medium of content and presentation. Follow the Powerpoint template to be provided in a separate email by the research committee.

3. The order of presentations will be determined by drawing lots one (1) hour before the start of the session.

4. Oral presentations must be completed in ten (10) minutes, followed by a five (5) minute question and answer portion. Two (2) warning signals will be sounded at the five (5) minute mark and at the eight (8) minute mark. One (1) point will be deducted from the total score for every minute or fraction of a minute of overtime.

5. Judges will select the winners of the proffered/platform session based on a grading rubric. Decisions rendered by the panel of five (5) esteemed judges on presentation day are final.

6. Additional reminders for finalists:
   - Be early to compose yourself and maximize technical preparations.
   - Dress code is business formal.
   - Review the judging criteria and follow the prescribed presentation format.

7. The winners will be announced during the Closing Ceremonies.

**Criteria for Judging:**

**PRE-JUDGING**
- Originality – 10%
- Significance of Research Question – 10%
- Methodology – 10%
- Study Population and Sample Size – 10%
- Appropriateness of Statistical Tests – 10%
- Internal Validity – 10%
- Clarity, Style and Prose of Content – 10%

**PRESENTATION**
- Formal Presentation and Visual Aids – 15%
- Knowledge of the Research (Q&A) – 15%

**TOTAL** – 100%

**Prizes**

Winners will receive trophy awards with the corresponding cash prizes:

- 1st Place: Php 25,000
- 2nd Place: Php 20,000
- 3rd Place: Php 15,000

All finalists will be given certificates of presentation.
PSP 72ND ANNUAL CONVENTION
RESEARCH COMPETITION

POSTER PRESENTATIONS – GUIDELINES / RULES

Abstract Submission

1. All members of the Philippine Society of Pathologists, Inc. (Junior, Diplomate, and Fellow members) are eligible to participate in the 72nd PSP Annual Convention research poster competition.
2. The abstract submission period for the 72nd PSP Annual Convention is until March 27, 2023, 11:59 PM. Only case reports may be entered into the Research Poster Contest.
3. Strict adherence to the provided template for abstract submissions is required. Please refer to the template provided at the end of this document. Abstracts must be written in English and should contain the research title, background, case description, summarized discussion and conclusion, not in excess of 250 words. Use of symbols is permitted but extensive abbreviations are discouraged.
4. No limit is imposed as to the number of abstracts a researcher may submit, however, a principal author may present no more than two (2) posters during the event. The Philippine Society of Pathologists, Inc. reserves the right to select the abstract to be presented during the session. There are no imposed limits for co-authorship.
5. Abstract PDF files (.pdf) must be submitted to PSP72ndAC.research@gmail.com with the file and email subject title being: “POSTER_(Initials)_(Title)” (ex. POSTER_AKP_Case report title). Once submitted, no further changes or revisions may be executed. Anonymized copies will be forwarded for judging.
6. Fifteen (15) interesting cases will be selected for Poster presentation. Participants will be notified through email regarding the acceptance or rejection of their entries no later than April 14, 2023 (Friday). Upon acceptance for presentation, the author must immediately register for the convention if he/she has not yet done so.
7. Prior to the annual convention, the research entry must not have been published elsewhere.

Poster Presentation

1. Please refer to the diagram below to serve as a template for the poster format.
2. The poster title, authors, institution/s and institution logo must be placed in the poster heading. The required poster size is 180 cm in total length and 90 cm in total width, printed on tarpaulin material % submitting author.

<table>
<thead>
<tr>
<th>L: 20 cm</th>
<th>W: 20 cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>[Poster Number]</td>
<td>[Heading: Title, Authors, Affiliations, Logo]</td>
</tr>
<tr>
<td>L: 160 cm</td>
<td>W: 90 cm</td>
</tr>
<tr>
<td>[Poster Content]</td>
<td></td>
</tr>
</tbody>
</table>

* Content must be readable from a distance of 10 meters.
* Maximize use of images, diagrams, tables and figures.
* No imposed limits for word count or poster design.
3. English is the required medium of content and presentation.

4. Authors of accepted abstracts must set-up their posters at the Grand Ballroom of the Shangri-la Hotel, The Fort, BGC, Taguig by 9:00 AM of April 20, 2023, to be removed by 9:00 PM of April 22, 2023. All unclaimed posters will be taken down and disposed of by the organizers thereafter.

5. Authors are requested to be on standby at the poster session venue by 12:30 PM of April 21, 2023 (Friday) in preparation for judging at 1:00 PM to 2:00 PM. Tags will be provided to identify participants.

6. Judges will select the winners of the poster session based on a grading rubric. Decisions rendered by the panel of seven (7) roving judges on presentation day are final.

7. The winners will be announced during the Closing Ceremonies.

**Criteria for Judging:**

**PRE-JUDGING**

- Originality – 10%
- Significance of the Case – 10%
- Completeness of Case Presentation – 40%
- Clarity, Style and Prose of Content – 10%
- Knowledge of the Case (Q&A) – 10%
- Poster Aesthetics – 20%

**TOTAL** – 100%

**Prizes**

Winners will receive trophy awards with the corresponding cash prizes:

- 1st Place: Php 17,500
- 2nd Place: Php 15,000
- 3rd Place: Php 10,000

All finalists will be given certificates of presentation.

**Publication with the Philippine Journal of Pathology**

Case report manuscripts of winning research posters will be published in the Philippine Journal of Pathology following revisions based on judges’ reviews and final editing. Worthy non-winning papers may also be published in the PJP upon acceptance by the editor, subject also to revisions based on judges’ reviews and final editing. Proper documentation of copyright transfer will be executed following official PJP protocol.
### ORAL PRESENTATION JUDGES

<table>
<thead>
<tr>
<th>Judge</th>
<th>Institutions and Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Daphne C. Ang, MD, DPSP</strong></td>
<td>De Los Santos Medical Center&lt;br&gt;Chinese General Hospital and Medical Center&lt;br&gt;St. Luke’s Medical Center, Quezon City&lt;br&gt;Philippine Children’s Medical Center&lt;br&gt;Philippine Airport Diagnostics Laboratory&lt;br&gt;Molecular Diagnostics Laboratory by Detoxicare&lt;br&gt;Premium Medical Laboratory&lt;br&gt;Chinese General Hospital&lt;br/Cardinal Santos Medical Center&lt;br&gt;Makati Medical Center&lt;br/St. Luke’s Medical Center, Global City&lt;br&gt;Lung Center of the Philippines</td>
</tr>
<tr>
<td><strong>Jared M. Billena, MD, DPSP</strong></td>
<td>Western Visayas Medical Center&lt;br/The Medical City Iloilo&lt;br/Iloilo Doctors’ College of Medicine</td>
</tr>
<tr>
<td><strong>Edwin L. Munoz, MD, DPSP</strong></td>
<td>Cardinal Santos Medical Center&lt;br/Asian Hospital and Medical Center&lt;br/St. Luke’s Medical Center, Global City&lt;br/St. Luke’s Medical Center, Quezon City&lt;br/Chinese General Hospital and Medical Center&lt;br/Philippine Children’s Medical Center&lt;br/The Medical City, Ortigas&lt;br/Philippine General Hospital</td>
</tr>
<tr>
<td><strong>Sheryl Q. Racelis-Andrada, MD, DPSP, PHSAE</strong></td>
<td>Mariano Marcos Memorial Hospital and Medical Center&lt;br/Mariano Marcos State University&lt;br/University of Northern Philippines</td>
</tr>
<tr>
<td><strong>Joshua T. Uyboco, MD, DPSP, RMT</strong></td>
<td>Metro Davao Research and Medical Center&lt;br/Accu-Lab Medical Systems, Inc.&lt;br/Brokenshire College School of Medicine</td>
</tr>
</tbody>
</table>

### POSTER PRESENTATION JUDGES

<table>
<thead>
<tr>
<th>Judge</th>
<th>Institutions and Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Jose Jasper L. Andal, MD, DPSP</strong></td>
<td>Philippine Orthopedic Center&lt;br/St. Luke’s Medical Center, Quezon City&lt;br/St. Luke’s Medical Center, Global City&lt;br/Lung Center of the Philippines</td>
</tr>
<tr>
<td><strong>Kevin A. Elomina, MD, DPSP</strong></td>
<td>Emilio Aguinaldo College of Medicine Medical Center&lt;br/Pagamutan ng Dasmariñas&lt;br/De La Salle Medical and Health Sciences Institute College of Medicine</td>
</tr>
<tr>
<td><strong>Ira Doressa Anne L. How, MD, DPSP</strong></td>
<td>National Kidney and Transplant Institute&lt;br/Victoriano R. Potenciano Medical Center</td>
</tr>
<tr>
<td><strong>Aldin A. Legaspi, MD, DPSP</strong></td>
<td>Allied Care Experts Dumaguete Doctors, Inc.&lt;br/Negros Polymedic Hospital&lt;br/Negros Oriental Provincial Hospital&lt;br/NuiqCare Diagnostic Laboratory</td>
</tr>
<tr>
<td><strong>Manuelito A. Madrid, MD, FPSP</strong></td>
<td>St. Luke’s Medical Center, Quezon City&lt;br/St. Luke’s Medical Center, Global City&lt;br/Philippine Children’s Medical Center&lt;br/Diliman Doctors Hospital</td>
</tr>
<tr>
<td><strong>Pier Angeli D.R. Medina, MD-MBA, DPSP</strong></td>
<td>The Medical City, Ortigas&lt;br/Pasig City Children’s Hospital&lt;br/Ateneo School of Medicine and Public Health&lt;br/San Beda University College of Medicine</td>
</tr>
<tr>
<td><strong>Ansarie P. Salpin, MD, FPSP</strong></td>
<td>Iloilo Doctors’ Hospital&lt;br/Medicus Medical Center&lt;br/West Visayas State University Medical Center</td>
</tr>
<tr>
<td>NAME</td>
<td>INSTITUTION</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------</td>
</tr>
<tr>
<td>Ermine Myrrhlet N. Bañares</td>
<td>University of Santo Tomas Hospital</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
</tr>
<tr>
<td>Rowen T. Yolo</td>
<td></td>
</tr>
<tr>
<td>Celestine Marie G. Trinidad</td>
<td></td>
</tr>
<tr>
<td>Charles Joseph L. Bernardo</td>
<td>St. Luke’s Medical Center – Quezon City</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
</tr>
<tr>
<td>Daphne C. Ang</td>
<td></td>
</tr>
<tr>
<td>Claire Anne Therese M. Hemedez</td>
<td></td>
</tr>
<tr>
<td>Jose Jasper L. Andal</td>
<td></td>
</tr>
<tr>
<td>Rubi Li</td>
<td></td>
</tr>
<tr>
<td>Yancel Mascardo</td>
<td></td>
</tr>
<tr>
<td>Alizza Mariel S. Espiritu</td>
<td></td>
</tr>
<tr>
<td>Josephine Matudan Babida</td>
<td></td>
</tr>
<tr>
<td>Aaron Pierre P. Calimag</td>
<td>National Kidney and Transplant Institute</td>
</tr>
<tr>
<td>Co-Author:</td>
<td></td>
</tr>
<tr>
<td>B. Januario Antonio. D. Veloso</td>
<td></td>
</tr>
<tr>
<td>Rebecca Rivera-Nagtalon</td>
<td>St. Luke’s Medical Center – Global City</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
</tr>
<tr>
<td>Daphne C. Ang</td>
<td></td>
</tr>
<tr>
<td>Jose Jasper L. Andal</td>
<td></td>
</tr>
<tr>
<td>Joseph Gary C. Sanchez, Jr.</td>
<td>Vicente Sotto Memorial Medical Center</td>
</tr>
<tr>
<td>Co-Author:</td>
<td></td>
</tr>
<tr>
<td>Kathrina S. Perez</td>
<td></td>
</tr>
</tbody>
</table>
ABSTRACT

VALIDITY OF THE SINGAPORE GENERAL HOSPITAL WEB-BASED PHYLLODES TUMOR RECURRENCE RISK ASSESSMENT TOOL AMONG PATIENTS SEEN IN A TERTIARY HOSPITAL IN METRO MANILA, PHILIPPINES: A 5-YEAR RETROSPECTIVE COHORT STUDY

Ermine Myrrhlet N. Bañares, MD1*, Rowen T. Yolo, MD, MHPEd1,2, Celestine Marie G. Trinidad, MD1,2

1Department of Anatomic Pathology, University of Santo Tomas Hospital, España, Manila, Philippines
2Faculty of Medicine and Surgery, University of Santo Tomas, España, Manila, Philippines

* ermsbanare@gmail.com || España Blvd, Sampaloc, Manila, 1015 || (02) 8731-3001

INTRODUCTION: Phyllodes tumor is a rare breast tumor which accounts for 0.3 – 1.0% of all breast tumors. Although mostly benign, recurrences in 2-3 years still occur with noted higher grade. In the Philippines, there are very few data regarding Phyllodes tumor, especially their recurrence and outcome. In 2011, Tan and colleagues from the Singapore General Hospital (SGH) developed an electronic calculator nomogram tool referred to as the Singapore Nomogram Phyllodes Tumor Risk Assessment Tool. This tool integrates the inputs of histopathologic information based on stromal Atypia, stromal Mitotic count, presence of stromal Overgrowth and Surgical margin status (AMOS) criteria. Calculation of Recurrence Free Score (RFS) is automated through a computerized program at the website which gives the probability of recurrence free survival of patients in 1, 3, 5 and 10 years.

OBJECTIVE: The aim of this study was to validate the said tool in Phyllodes Tumor patients in the Philippine setting together with standardization of reports to be able to utilize the nomogram in the near future.

METHODS: Forty nine (49) out of seventy phyllodes tumor patients at the University of Santo Tomas Hospital from January 1, 2017 to December 31, 2019 was included in the study. These are the patients who had at least 1 year follow up. Permanent tissue slides were reviewed by three independent pathologists based on atypia, mitosis, stromal overgrowth and margin status. The probability of concordance between the predicted and observed survival was evaluated by using Harell’s c index. The proportion of phyllodes tumor parameters in histopathologic reports were also determined.

RESULTS: Kaplan Meier curve for recurrence free survival probability showed a 1-year RFS of 95.94%, 3-year RFS of 77.07% and 5-year RFS of 66.06%. Harell’s c index showed concordance validity of 0.99, 0.88 and 0.88, respectively. Majority of the phyllodes tumor cases were benign at 63%, followed by borderline patients at 22% and 14% were malignant. Of the malignant cases, 6% (n=3) had metastasis. Borderline and malignant patients (n=11, 22%) underwent adjuvant therapy (radiotherapy). The slide review showed that most cases had none or mild atypia (47%), followed by moderate atypia (37%) and severe atypia (16%). The number of mitoses has the median number per 10 hpf of 2 with a range of 1 to 35 mitotic figures/10 hpf, Stromal overgrowth was seen in 35% and 20% had positive margin involvement. For patients with negative margins, a median distance of 1.0 mm with a range of fraction of a mm-10.0 mm was noted. Lastly, review of the official histopathology reports showed that all histopathology reports reported mitoses per 10 hpf. However, lowest proportion of available parameter was recorded for distance from margin (74%).

CONCLUSION: Analysis of the Philippine based cohort of women with phyllodes tumor, using a validation of the Singapore General Hospital web based- Phyllodes Tumor Recurrence Risk Assessment Tool, yielded a Harell’s concordance index of 0.99, 0.88 and 0.88 for 1, 3 and 5 years follow up, respectively. This supports the Phyllodes Tumor Recurrence Risk Assessment Tool by Singapore General Hospital is able to predict recurrence free survival among Filipino women with phyllodes tumor of the breast. Thus, the use of the tool for patients in our local setting may be beneficial. It was also derived that not all parameters are being regularly reported in the histopathology reports. The only parameter consistently reported was the number of mitoses. In order to utilize the risk assessment tool, standardization of reports should be practiced. In this study, distance form margin was included, although not indicated in the tool, as part of standardization, it was found that only 74% of reports indicate distance to margins.
INTRODUCTION: Ovarian cancer is one of the leading causes of mortality in women. In 2020, 5,395 (6.2%) of diagnosed malignancies in females are ovarian in origin. It also ranks third among gynecologic malignancies after cervical and uterine cancer. The prevalence in Asian/Pacific women is 9.2 per 100,000 population. Increased mortality and poor prognosis in ovarian cancer is caused by asymptomatic growth and delayed or absent symptoms for which about 70% of women have advanced stage (III/IV) by the time of diagnosis. The most commonly associated gene mutations are Breast Cancer gene 1 (BRCA1) which is identified in chromosome 17q21 and Breast Cancer gene 2 (BRCA2) identified in chromosome 13. Both proteins function in the double strand DNA break repair pathway especially in the large framework repair molecules. Olaparib is a first-line drug used in the management of ovarian cancer. It targets affected cells by inhibition of poly (ADP-ribose) polymerase (PARP) activity which induces synthetic lethality in mutated BRCA1/2 cancers by selectively targeting tumor cells that fail to repair DNA double strand breaks (DSBs).

OBJECTIVES: The general objective of this study is to determine the prevalence of pathogenic somatic mutations in BRCA1 and BRCA2 among patients diagnosed of having ovarian cancer. The specific objectives are: 1) to characterize the identified variants into benign/no pathogenic variant identified, variant of uncertain significance (VUS), and pathogenic and 2) to determine the relationship of specific mutations detected with histomorphologic findings and clinical attributes.

METHODS: Ovarian cancer tissues available in St. Luke's Medical Center Human Cancer Biobank and Formalin fixed paraffin embedded (FFPE) tissue blocks diagnosed as ovarian cancer from year 2016 to 2020 was included. Determination of the prevalence of somatic BRCA1 and BRCA2 mutations using next generation sequencing.

RESULTS: A total of 60 samples were processed, three samples were excluded from the analysis due to inadequate number of cells. In the remaining 57 samples diagnosed ovarian tumors, pathogenic BRCA1/2 variants were identified in 10 (17.5%) samples. Among the BRCA1/2 positive samples, 3 (5.3%) BRCA1 and 7 (12.3%) BRCA2 somatic mutations were identified.

CONCLUSIONS: In conclusion, identification of specific BRCA1/2 mutations in FFPE samples with the use next generation sequencing plays a big role in the management of ovarian cancer particularly with the use of targeted therapies such as olaparib. The use of this drug could provide a longer disease-free survival for these patients. Furthermore, we recommend that women diagnosed with ovarian cancer should be subjected to genetic testing regardless of the histologic subtypes or clinical features. Lastly, genetic testing should be done along with proper genetic counselling especially to patients who are susceptible to these mutations.
ABSTRACT

PROFILING OF GENETIC MUTATIONS IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA USING FLUORESCENCE IN-SITU HYBRIDIZATION FROM 2014 TO 2021 AT THE NATIONAL KIDNEY AND TRANSPLANT INSTITUTE

Aaron Pierre P. Calimag, MD*, Januario Antonio D. Veloso, MD

Department of Pathology and Laboratory Medicine National Kidney and Transplant Institute, Quezon City, NCR

*pierre_calimag@yahoo.com || East Avenue, Quezon City, Metro Manila, 1100 || (02) 8981-0300 loc 1145

INTRODUCTION: Among patients with Acute Myeloid Leukemia, the karyotype at diagnosis is an important prognostic indicator for predicting outcomes. Several studies have been done to identify the most common cytogenetic abnormalities seen in patients in other countries, however, limited studies have been done in our setting.

OBJECTIVES: The study aims to determine the most common abnormalities present among patients with AML referred for Fluorescence in-situ Hybridization at the National Kidney and Transplant Institute.

METHODS: The study included 131 adult patients with a mean age of 46. Fluorescence in-situ Hybridization was used to identify the following cytogenetic abnormalities: t(8;21), 11q23 (MLL), 16q22 (CBFB- MYH11), t(15;17) (PML/RARA), t(9;22) (BCR/ABL), 7q31 deletion, and Monosomy 7.

RESULTS: FISH was negative in 40% (n=53) of patients. 22% (n=29) of patients have multiple abnormalities, the most common involves 7q31 deletion and t(8;21) (15% n =20). Patients with negative results, and patients with multiple cytogenetic abnormalities are commonly seen within the 41 to 50 age group. 7q31 deletion is the most frequently identified cytogenetic abnormality among patients with single abnormality (n=17, 13%) present and is most frequently identified gene among patients with multiple abnormalities (n=26). 7q31 deletion is more frequently observed among patients within the ages 51 to 60 years old and with Acute Myeloid Leukemia with monocytic differentiation.

CONCLUSION: Epidemiologic studies are needed to better understand the similarities and differences seen from previously reported incidences.
ABSTRACT

A CROSS-SECTIONAL STUDY ON THE COMPARISON OF SALIVA-BASED AND NASOPHARYNGEAL/OROPHARYNGEAL SWAB-BASED PCR TESTS FOR SARS-CoV-2 DETECTION IN ACUTELY ILL PATIENTS IN THE EMERGENCY DEPARTMENT OF A TERTIARY HOSPITAL IN THE PHILIPPINES

Rebecca R. Nagatalon, MD*, Jose Jasper L. Andal, MD, Daphne C. Ang, MD
Institute of Pathology, St. Luke’s Medical Center – Global City
* rrnagtalon@gmail.com || 5th Avenue, Taguig, Metro Manila, 1634 || (02) 8789-7700

INTRODUCTION: The global outbreak of the coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome (SARS-CoV-2) virus. The combined nasopharyngeal and oropharyngeal specimens are the current sample of choice in the determination of COVID-19 infection. Saliva is used as an alternative specimen as it is non-invasive and minimizes the exposure of healthcare staff.

OBJECTIVES: This study aims to determine the accuracy of saliva-based specimen in the detection of SARS-CoV-2 using NPS/OPS real time polymerase chain reaction (RT-PCR) test amongst acutely ill patients in the emergency department of a Tertiary hospital in the Philippines.

METHODS: This is an analytical cross-sectional study conducted among suspected COVID-19 patients admitted in the emergency department of St. Luke’s Medical Center - Global City, from April to May 2021. RT-PCR was performed on the paired NPS/OPS and saliva samples using Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescence Probing) (Sansure Biotech Inc., Hunan Province, P.R. China). Comparison of the sensitivity and specificity of each specimen type was performed, as well as, the comparison of differences between CT values.

RESULTS: One hundred thirty-two sample pairs of NPS/OPS and saliva samples were collected in the emergency department from April 2021 to May 2021. The overall sensitivity of saliva-based samples is 76.56% (95% CI, 64.87-85.25). No significant difference in CT values were noted in the ORF1ab and N genes for both NPS/OPS and saliva-based specimens.

CONCLUSION: Despite the limited number of samples from symptomatic patients used in this study, this study shows that saliva-based specimens may be used as an alternative specimen. These can be used in symptomatic patients, preferably those in the earlier onset of their infection.
INTRODUCTION: Recent studies assessing routine appendectomies done for mucinous ovarian tumors (MOTs) commonly observed no mucinous appendiceal neoplasms among grossly normal appendices, proposing selective appendectomy only on grossly abnormal appendices.

OBJECTIVE: This study investigates the reliability of a grossly normal appendix in excluding a mucinous appendiceal neoplasm in a large sample of MOTs.

METHODS: Final biopsy reports of MOTs with concurrent appendectomy from 2002 to 2022 in a single institution were reviewed. Cases of MOT were grouped according histologic type and relevant gross features of the ovarian tumor. The diagnostic value of a grossly normal appendix in each group was assessed.

RESULTS: Six hundred twelve (612) cases of MOTs with appendectomies were identified, including 421 benign MOTs, 75 borderline MOTs, and 116 malignant MOTs. Only 23 out of 612 appendices had mucinous neoplasms (3.76%). Overall, the gross features of the appendix were associated with the histologic absence of a mucinous appendiceal lesion (P<.001, n=612), with correlation highest among borderline MOTs. Among malignant MOTs with primary gross features, no association was present (P=.95, n=61).

CONCLUSION: Despite the rare occurrence of mucinous appendiceal neoplasms during resection for mucinous ovarian tumors, the presence of a grossly normal appendix cannot exclude a mucinous neoplasm.
<table>
<thead>
<tr>
<th>NAME</th>
<th>INSTITUTION</th>
<th>RESEARCH TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Marielle G. Belmonte</td>
<td>Makati Medical Center</td>
<td>Unexpected Seminoma in a 34-year-old Phenotypical Female</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Steven O. Truelen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Redante D. Mendoza</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeffrey S. So</td>
<td></td>
</tr>
<tr>
<td>Josh Matthew B Chen</td>
<td>St. Luke’s Medical Center – Quezon City</td>
<td>B-Cell Lymphoblastic Lymphoma in the Cervix of a 44-year-old Female: A Case Report and Review of Literature</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leo Francis N. Aquilizan</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alejandro E. Arevalo</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claire Anne Therese M. Hemedez</td>
<td></td>
</tr>
<tr>
<td>Jasher L. Chua</td>
<td>Philippine General Hospital</td>
<td>Right Atrial Isomerism: An Autopsy Approach from the Philippines</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marvin C. Masalunga</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nelson T. Geraldino</td>
<td></td>
</tr>
<tr>
<td>Joan Marie Diestro</td>
<td>West Visayas State University Medical Center</td>
<td>Aberrant β-hCG Expression of Diffuse Large B-cell Lymphoma, Anaplastic Variant Involving the Meckel Diverticulum</td>
</tr>
<tr>
<td>Co-Author:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Margie Gayapa</td>
<td></td>
</tr>
<tr>
<td>Jeffrey D. Domingo</td>
<td>St. Luke’s Medical Center – Quezon City</td>
<td>A Case of Extensive Facial Primitive Myxoid Mesenchymal Tumor of Infancy: An Approach to Diagnosis and Review of Literature</td>
</tr>
<tr>
<td>Co-Author:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ma. Cristina D.C. Briones</td>
<td></td>
</tr>
<tr>
<td>Carmela Claire A. Ferrer</td>
<td>National Kidney and Transplant Institute</td>
<td>Anaplastic Lymphoma Kinase-Positive Large B-cell Lymphoma: A Rare Entity</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Januario Antonio D. Veloso</td>
<td></td>
</tr>
<tr>
<td>Carmela Claire A. Ferrer</td>
<td>National Kidney and Transplant Institute</td>
<td>A Rare Case of Myxoid Adrenal Cortical Carcinoma</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pamela R. Delos Reyes-Murillo</td>
<td></td>
</tr>
<tr>
<td>Danielle Anne G. Gonong</td>
<td>Philippine Children’s Medical Center</td>
<td>Synchronous Sertoli-Leydig Cell Tumor with Retiform Pattern and Pleuropulmonary Blastoma in a 3-Year-Old with DICER1 Syndrome</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carol C. Tan-Hernandez</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Josy Naty M. Venturina-Fano</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claire Anne Therese M. Hemedez</td>
<td></td>
</tr>
</tbody>
</table>
## POSTER PRESENTATIONS – FINALISTS

<table>
<thead>
<tr>
<th>NAME</th>
<th>INSTITUTION</th>
<th>RESEARCH TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kris Raychelle R. Godoy</td>
<td>St. Luke’s Medical Center – Quezon City</td>
<td>Mesonephric-Like Adenocarcinoma of the Uterus: A Case Report</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria Lourdes L. Goco</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Claire Anne Ther M. Hemedez</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jose B. Moran</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kris Raychelle R. Godoy</td>
<td>St. Luke’s Medical Center – Quezon City</td>
<td>Primary Synovial Sarcoma of the Parotid Gland in a Filipino Female: A Case Report</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ann Margaret V. Chang</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jose Jasper L. Andal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sherwin B. Biasura</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beverly P. Carbonell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kim Pearl Mai P. Pajarit</td>
<td>Quirino Memorial Medical Center</td>
<td>Primary Osseous Angiosarcoma: A Case Report</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jose Jasper L. Andal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Celestine Marie G. Trinidad</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roxanne Joy P. Quiton</td>
<td>Ilocos Training Regional and Medical Center</td>
<td>A Rare case of Adult Onset Xanthogranuloma Presenting as Intracranial Mass</td>
</tr>
<tr>
<td>Co-Author:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jimmy S. Rosales</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seth Andrew J. Salih</td>
<td>Philippine General Hospital</td>
<td>Chordoid Glioma: A Case of an Intracranial Mass in a Forty-four year old Female</td>
</tr>
<tr>
<td>Co-Authors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mark Angelo C. Ang</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edwin L. Muñoz</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geneda Camille F. Sebial-Orteza</td>
<td>Mariano Marcos Memorial Hospital</td>
<td>Growing Teratoma Syndrome: A Rare Tumor Transformation</td>
</tr>
<tr>
<td>Julienne Ross C. Yarra</td>
<td>St. Luke’s Medical Center – Quezon City</td>
<td>A Case of Hepatoid Adenocarcinoma of the Colon with Metastasis to the Liver: A Potential Diagnostic Confusion in Patients Presenting with Liver Mass</td>
</tr>
<tr>
<td>Co-Author:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glenda Lyn Y. Pua</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
INTRODUCTION: In this case report we discuss a 34-year-old phenotypical female, previously diagnosed with Mayer Rokitansky Küster-Hauser Syndrome (MRKHS), having histopathologic features compatible with seminoma.

CASE DESCRIPTION: The patient presented with an acute abdomen and underwent exploratory laparotomy with bilateral oophorectomy. Histopathology confirmed that the patient had cryptorchid testes, with the right having malignant transformation.

DISCUSSION: Androgen insensitivity syndrome (AIS) is a rare disorder due to mutations in the androgen receptor resulting in sexual development disorders in 46, XY males. A close differential to AIS, also presenting as phenotypically female but with 46, XX genotype is Mayer Rokitansky Küster-Hauser Syndrome (MRKHS). In adolescence to adulthood, AIS and MRKHS may have similar presentations. Karyotyping is vital in differentiating and confirming the diagnosis of AIS or MRKHS. Misdiagnoses have significant consequences. There is an increased risk for testicular malignancy in both AIS and cryptorchidism.

CONCLUSION: The patient presented with primary amenorrhea and was previously diagnosed with MRKHS. Because of an inaccurate early diagnosis, she failed to receive appropriate care resulting in the development of seminoma. This case report aims to contribute to the limited literature on AIS in the local setting and prevent misdiagnosis of AIS.

KEYWORDS: androgen insensitivity syndrome, Mayer Rokitansky Küster-Hauser Syndrome, seminoma
ABSTRACT

B-CELL LYMPHOBLASTIC LYMPHOMA IN THE CERVIX OF A 44-YEAR-OLD FEMALE: A CASE REPORT AND REVIEW OF LITERATURE

Josh Matthew B. Chen, MD1*, Leo Francis N. Aquilizan, MD2, Alejandro E. Arevalo, MD1, Claire Anne Therese M. Hemedez, MD1

1St. Luke’s Medical Center – Quezon City, Institute of Pathology, Quezon City, NCR
2St. Luke’s Medical Center – Quezon City, Department of Obstetrics and Gynecology, Quezon City, NCR

* jmbchen@stlukes.com.ph || 279 E. Rodriguez Sr. Ave., Quezon City, 1112 Metro Manila || (02) 87230101

INTRODUCTION: B-Cell Lymphoblastic Lymphoma (BLL) is a highly malignant subtype of Non-Hodgkin Lymphoma committed to B-cell lineage. Involvement of the female genital tract is rare with fewer than 1% of extra-nodal lymphomas. Because of its low incidence, management strategies have been reliant on case series.

CASE DESCRIPTION: We present a case of a 44-year-old female who sought consult for uterine bleeding with no significant past medical history. Pap smear was unremarkable while her transvaginal ultrasound revealed a mass. Biopsy was done and revealed dense proliferation of small to medium sized lymphoid cells. Immunohistochemical stains yielded positive staining for Leukocyte common antigen (LCA), CD79a, CD99, and Terminal deoxynucleotidyl transferase (Tdt). Hence, a diagnosis of BLL was made.

DISCUSSION: Extra-nodal lymphoma of uterine origin accounts for fewer than 1% of extra-nodal cases. It accounts for less than 0.5% in the cervix and BLLs are considered as among the rarer types. Its clinical presentation is non-specific with uterine bleeding being the most common. It may or may not present as a mass. Microscopic appearance is similar to that of nodal lymphomas. Immunohistochemical studies are necessary to diagnose this neoplasm. It is potentially curable with chemotherapy, radiotherapy, surgery, either alone or in combination.

CONCLUSION: BLL involving the cervix is a very rare manifestation of extra-nodal lymphoma. Clinical manifestations are non-specific. It requires biopsy as well as immunohistochemical studies to properly identify this specific entity. No definite guidelines yet for proper management but several reports have shown good survival rates with combination chemotherapy.

KEYWORDS: cervix, lymphoblastic lymphoma
RIGHT ATRIAL ISOMERISM: AN AUTOPSY APPROACH FROM THE PHILIPPINES

Jasher L. Chua, MD1*, Marvin C. Masalunga, MD2, Nelson T. Geraldino, MD3

1Department of Laboratories, Philippine General Hospital, Manila, National Capital Region
2Department of Pathology, Vicente Sotto Memorial Medical Center, Cebu City, Region VII
3Department of Pathology and Laboratories, Asian Hospital and Medical Center, Muntinlupa, NCR

* rehsaj@gmail.com || 1170 Benavidez St. Tondo, Manila

INTRODUCTION: Right atrial isomerism (RAI) is a subset of heterotaxy syndrome, defined as a “mirror-image,” abnormal assembly of the thoraco-abdominal organs caused by right-left axis disorientation during embryonic development. Right atrial isomerism results in the duplication of right-sided structures with bilateral right atria and atrial appendages, and absence of left-sided structures.

CASE DESCRIPTION: A 3-month-old male presented with a history of dyspnea, cyanosis, and progressive lethargy. While admitted, the patient’s respiratory distress worsened, with O2 saturation levels as low as 35%. The patient’s condition progressively deteriorated, leading to his demise. Autopsy examination revealed multiple congenital heart defects, including bilateral right atria, bilateral superior vena cava, septal defects, double-outlet right ventricle, and extracardiac total anomalous pulmonary venous return. Other abnormalities include bilateral trilobed lungs, bilateral eparterial bronchi, symmetrical liver, asplenia, and intestinal malrotation.

DISCUSSION: This is the first documented case of RAI in the Philippines. A modified window method was used to better illustrate the septal defects of a small heart, with cuts up to the base of the heart to expose bilateral atria. Extreme care was taken to dissect yet preserve the vasculature of the lung and liver to showcase the mirror image in RAI.

CONCLUSION: Mortality rate of heterotaxy syndrome remains high (40%) with median age of death at 6 months. The case brings to attention the need for basic prenatal screening (ultrasound and echocardiography) and postnatal screening (chest X-ray and pulse oximetry). Early diagnosis and intervention are essential in managing the complex clinical course of patients with RAI.

KEYWORDS: right atrial isomerism, heterotaxy syndrome, autopsy
INTRODUCTION: Elevation of the beta subunit of human chorionic gonadotrophin (β-hCG) in serum is rarely encountered in lymphomas. Even rarer, is its incidental occurrence in a lymphoma found in Meckel diverticulum.

CASE DESCRIPTION: This case presents an 11-year-old girl with a month-long history of abdominal pain and palpable hypogastric mass. Imaging showed a huge abdominopelvic mass (18.15x12.4x8.12cm) associated with elevated serum β-hCG, CA125 and LDH levels, thus an ovarian germ cell tumor was considered. Laparotomy was done with a finding of a perforated Meckel diverticulum. The resected ileum was sent for biopsy and showed transmural infiltration by a malignant neoplasm seen as dyshesive sheets of large atypical lymphoid cells with occasional Reed-Sternberg-like cells. The neoplastic cells are positive for CD45, CD20, and CD30, whereas CD3 and ALK are negative. The immuno-morphologic findings are consistent with the anaplastic variant of diffuse large B-cell lymphoma. Aberrant β-hCG expression was also documented by immunohistochemistry.

DISCUSSION: In pediatric patients, identification of lymphoma aids in prognostication. Among non-Hodgkin lymphomas, the 5-year event-free survival rate of DLBCL is better (89%) than close differentials.

CONCLUSION: This is the first case of the anaplastic variant of DLBCL with aberrant expression of β-hCG involving the Meckel diverticulum. This emphasizes awareness as regards possible clinical and diagnostic confusion among β-hCG-producing clinical entities in reproductive age females. Among large cell lymphomas with RS-like cells, immuno-morphologic diagnosis is of paramount importance.

KEYWORDS: anaplastic, diffuse large B-cell lymphoma, human chorionic gonadotrophin, meckel diverticulum
INTRODUCTION: Primitive myxoid mesenchymal tumor of infancy (PMMTI) is a rare and newly recognized distinct soft tissue sarcoma with less than 50 cases reported worldwide. It is characterized by the BCL6 co-repressor (BCOR) gene internal tandem duplication (ITD) genetic alteration. Extensive information is still needed to further understand its clinicopathologic behavior that is fundamental to its successful management, particularly in cases with unresectable condition. This case is one of the most invasive PMMTI reported to date.

CASE DESCRIPTION: This is a case of a 14-month-old female presenting with a one-year history of rapidly enlarging, nontender, multinodular left hemifacial mass with myxoid and low-grade histologic features. Panel of immunohistochemical stains (IHCs) showed positive expression to vimentin, CD99, SATB2 and cyclin D1, compatible with a sarcoma with BCOR genetic alteration. Next generation sequencing was performed detecting a BCOR (exon 15) – BCOR (exon 15) breakpoint, indicating presence of BCOR ITD, hence confirming the diagnosis of PMMTI.

DISCUSSION: PMMTI typically occurs within the first year of life and must be distinguished from other clinically and histologically related tumors in the spectrum of both benign and malignant conditions owing to its different management approach. Due to its local aggressiveness, complete surgical excision is the gold standard treatment. However, consensus treatment protocols for unresectable tumors are still lacking. Prognostic significance of the histological variation and insert size remains unknown.

CONCLUSION: This report highlights the importance of careful attention to histopathologic features, judicious use of IHCs and molecular studies in differentiating PMMTI from other soft tissue sarcomas.

KEYWORDS: primitive myxoid mesenchymal tumor of infancy, BCL6 co-repressor gene internal tandem duplication, soft tissue sarcoma
INTRODUCTION: Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (ALK+ LBCL) is a rare entity characterized by monomorphic large immunoblast-like or plasmablast-like neoplastic B-cells which frequently express epithelial membrane antigen (EMA) and ALK, as well as plasma cell markers. Diagnostic dilemma may arise as this tumor may mimic different entities due to overlapping immuno-morphologic features.

CASE DESCRIPTION: This is a case of a 25/M who presented with a soft palate mass. It was sent to our institution for review and immunohistochemical studies. Review showed a tumor composed of diffuse sheets, with occasional sinusoidal pattern, of monomorphic neoplastic cells showing round nuclei with prominent eosinophilic nucleoli, and abundant eosinophilic cytoplasm. Immunohistochemical studies using LCA, S-100, desmin, CD3, CD20, CD30, CD5, EMA, ALK, PAX-5, CD138, and MUM-1 were performed. Among these markers, LCA, ALK, EMA, PAX-5, CD138, and MUM-1 showed positive expression. A diagnosis of ALK+ LBCL was rendered.

DISCUSSION: ALK+ LBCL can be morphologically similar to Poorly Differentiated Carcinoma, Melanoma, Diffuse Large B-cell Lymphoma, and Plasmablastic Lymphoma. EMA and ALK expression may warrant consideration of Anaplastic Large Cell Lymphoma. Hence, immunohistochemical studies are needed to differentiate ALK+ LBCL from these mimickers. LCA, S-100, and desmin were initially done to determine the lineage of the neoplasm. T- and B-cell markers, as well as plasma cell markers, were requested to determine its the specific nature.

CONCLUSION: ALK+ LBCL is a rare B-cell neoplasm which can mimic other neoplasms. Hence, meticulous review of the case and proper recommendation of immunohistochemical studies is warranted to prevent diagnostic pitfalls.

KEYWORDS: anaplastic lymphoma kinase, lymphoma b-cell, lymphoma large b-cell diffuse, lymphoma large cell anaplastic
INTRODUCTION: Adrenocortical carcinoma is a rare tumor, especially the myxoid subtype with just about 50 reported cases to date. Diagnostic confusion with neoplasms with myxoid features may be encountered. Thus, utilization of the available multiparameter algorithms (i.e., Weiss scoring system) and immunohistochemical studies is essential in establishing the correct diagnosis.

CASE DESCRIPTION: This is a case of a 54/F who presented with a history of flank pain. Imaging studies showed a 20.7 x 13.9 x 14.3 cm large, lobulated, enhancing mass in the left suprarenal region. Grossly, a well-circumscribed, yellow to tan, soft mass measuring 20.8 x 14.4 x 4.1 cm was found at the superior pole. Histologic sections showed neoplastic cells forming sheets, trabecular, and papillary patterns, surrounded by a myxoid background. These cells have occasionally enlarged, round to ovoid, hyperchromatic to vesicular nuclei, with inconspicuous to prominent nucleoli, and abundant eosinophilic cytoplasm. Rare mitotic figures were seen. Necrotic debris and lymph-vascular invasion were identified. Melan-A, Inhibin, Synaptophysin, and Pancytokeratin stained positively. CK7, CK20, GATA-3, PAX-8, ALK, CAIX were not expressed. Ki-67 was at 15%. Hence, this was diagnosed as Myxoid Adrenocortical Carcinoma.

DISCUSSION: Given the tumor’s location and morphology, an ALK-rearranged Renal Cell Carcinoma and a Myxoid Adrenocortical Carcinoma were considered. Cytokeratin markers were performed to determine the primary site of the tumor. Inhibin, Melan-A, Synaptophysin, PAX-8, ALK, CAIX were not expressed. Ki-67 was at 15%. Hence, this was diagnosed as Myxoid Adrenocortical Carcinoma.

CONCLUSION: The diagnosis of Myxoid Adrenocortical Carcinoma entails appropriate usage of the known multiparameter scoring systems and immunohistochemical studies to prevent underrecognition of this malignancy.

KEYWORDS: adrenal cortex neoplasms, adrenal gland neoplasms, adrenocortical carcinoma
INTRODUCTION: DICER1 syndrome predisposes to neoplasms, such as, Sertoli-Leydig cell tumor and pleuropulmonary blastoma. Unfortunately, reports in this syndrome are sparse making diagnosis and treatment challenging.

CASE DESCRIPTION: A 3-year-old presented with fever, vomiting, and abdominal pain and tenderness. Computed tomography scan showed masses in the right lower abdomen and left hemithorax. Right salphingo-oophorectomy showed a complex mass measuring 10.0 x 8.1 x 4.7 cm with histopathology result of Sertoli-Leydig cell tumor with retiform pattern. Genetic studies showed mutated pathogenic DICER1 gene and a BRCA2 gene with uncertain significance. Subsequent lobectomy of the left hemithorax mass showed a cystic mass which measured 3.2 x 2.0 x 1.2 cm. Histopathologic features were compatible with Pleuropulmonary blastoma type 1.

DISCUSSION: Loss-of-function mutation and/or acquired somatic missense mutation of DICER1 gene result to several neoplasms. In this case, Sertoli-Leydig cell tumor with retiform pattern and Pleuropulmonary blastoma type 1 were observed synchronously. Sertoli-Leydig cell tumor is a rare ovarian neoplasm with proliferation of Sertoli and Leydig cells. Retiform pattern has cleft-like spaces lined by cuboidal or flattened cells. This tumor is positive for sex-cord immunohistochemistry markers. Pleuropulmonary blastoma is the most common primary lung neoplasm of childhood. Pleuropulmonary blastoma type 1 has expanded airspaces lined by alveolar or bronchial-type epithelium. Nodules resembling the morphology and immunophenotype of mesenchymal neoplasms may also be seen in this malignancy.

CONCLUSION: Diagnosis of neoplasms with predisposing genetic insults shall prompt genetic work-up for the holistic management of patients and their relatives.

KEYWORDS: DICER1 syndrome, pleuropulmonary blastoma, and Sertoli-Leydig cell tumor
INTRODUCTION: Mesonephric-like adenocarcinoma (MLA) is a rare malignancy representing about 1% of endometrial carcinomas. The diagnosis is challenging due to the presence of diverse architectural patterns and has been newly included in the World Health Organization 2020 classification of female genital tract tumors. The importance of this case report is to raise awareness of the characteristic histological features of MLA, and add to global data in clinico-pathological and molecular verification to clarify the histogenesis, biological behavior and possible treatment option.

CASE DESCRIPTION: A 66-year-old, presented with vaginal bleeding and thickened endometrium on ultrasound. Hysterectomy revealed a 2.3 x 2 x 1.3 cm. fungating mass in the fundal area with myometrial invasion. The tumor is comprised of cuboidal to columnar cells with mild to moderate nuclear atypia and exhibits diverse architectural patterns including papillary, micropapillary, glandular, retiform, glomeruloid and tubular pattern with focal eosinophilic luminal secretions. Immunohistochemical studies revealed diffuse positivity for GATA-3 and TTF-1, focal positivity for p16, wild-type expression for p53 and lack of expression for ER and PR. Next generation sequencing result include mutations in KRAS G12V (equivocal), CDKN1B W76, FAM123B P551fs*28, NKX2-1 (equivocal), and SPOP M177V.

DISCUSSION: The diagnosis of MLA is based on morphology recognition combined with immunohistochemical studies. Molecular analysis supports the diagnosis and for possible treatment strategy.

CONCLUSION: Despite its low-grade morphology, MLA is considered a high-grade endometrial carcinoma with high risk of recurrence and metastasis. Due to rarity of this disease, further research on the pathogenesis, and therapeutic strategy are yet to be determined.
INTRODUCTION: Primary synovial sarcoma (SS) of the parotid gland represents <3% of head and neck SS. It has a variety of histologic types: monophasic epithelial, monophasic fibrous, biphasic and poorly-differentiated. Among these, the monophasic and poorly-differentiated types together with an uncommon anatomic presentation poses the greatest diagnostic difficulty.

CASE DESCRIPTION: A 27-year-old, female presented with gradually enlarging pre-auricular mass and was misdiagnosed with nodular fasciitis on superficial parotidectomy. Tumor recurrence was noted seven months post-operation which warranted total parotidectomy. On review of both cases, the superficial parotidectomy slides showed hypocellular and hypercellular areas comprised of bland spindle cells in fascicular pattern with mitotic rate of 7/10 hpf. On the other hand, microsections of the total parotidectomy showed pleomorphic spindle cells in haphazard arrangement, increased mitosis and areas with geometric necrosis. Immunohistochemical stains were performed on both specimens and revealed diffuse positivity to TLE1, patchy positivity to EMA, equivocal to Desmin, and negative CK, P63, S100, SMA, CD34, myogenin, and CK 5/6. The tumor also showed SS18 (18q11.2) translocation via fluorescent in-situ hybridization (FISH), confirming the diagnosis of monophasic synovial sarcoma.

DISCUSSION: Recognition of primary synovial sarcoma of the parotid gland is difficult due to its unusual location and its histologic features that may overlap with other neoplasms. Immunohistochemical and cytogenetic studies are essential in establishing the diagnosis.

CONCLUSION: Head and neck synovial sarcomas are aggressive tumors with high recurrence rate thus warranting a definitive diagnosis on presentation. Aggressive management with surgical resection with or without radio/chemotherapy and close follow-up are warranted.
INTRODUCTION: Angiosarcomas are uncommon malignant vascular neoplasms derived from mesenchymal cells. Primary angiosarcomas of bone are even more uncommon, accounting for less than 1% of all angiosarcomas. The overall prognosis is poor, with a high rate of tumor-related deaths. Treatment remains controversial as this is a rare clinical entity.

CASE DESCRIPTION: A 59-year-old male presented with a 4-month history of reduced right elbow flexion secondary to a right arm injury. The radiograph showed significant lytic destruction of the proximal ulna and the lateral humeral epicondyle with a large soft tissue opacity on the proximal forearm and elbow. Right above-elbow amputation was performed. Grossly, a well-demarcated, firm to friable mass was seen arising from the epimetaphyseal area of the ulna. Histological evaluation revealed malignant round and polygonal cells arranged in sheets with vasoformative structures lined by atypical endothelial cells. Immunohistochemical staining demonstrated that the tumor cells were positive for CD31 and CK.

DISCUSSION: The clinical and radiologic findings of primary angiosarcomas of the bone are non-specific; the tumor may present as a solitary lytic mass with irregular borders. The differential diagnosis includes epithelioid hemangioendothelioma, epithelioid sarcoma, and metastatic carcinoma. The positivity of one vascular marker, in correlation with characteristic histomorphology, is necessary to confirm the diagnosis.

CONCLUSION: The present report underscores the diagnostic difficulty in this rare but highly aggressive disease entity. Because angiosarcomas sometimes show epithelioid histomorphology, careful pathologic examination and a panel of immunohistochemical stains are necessary for the definitive diagnosis.

KEYWORDS: angiosarcoma, immunohistochemistry, vascular neoplasm
INTRODUCTION: Juvenile xanthogranuloma is a relatively common form of non-Langerhans cell histiocytosis presenting as multiple cutaneous lesions in children. Adult xanthogranuloma, on the other hand, occurs in the fourth decade of life and is less common. It could occur in extracutaneous sites such as the central nervous system. The objective of this case report is to discuss a rare case of an adult with intracranial mass, how the patient was diagnosed, and its impact in the patient’s management after surgery.

CASE DESCRIPTION: This is a case of a 59-year-old male presenting with a 4-month history of right-sided body weakness progressing to generalized body weakness and inability to ambulate. Cranial imaging revealed features suggestive of an intracranial mass. Since the mass was deemed resectable, excision of mass was done and was sent for histopathologic and immunohistochemical studies.

DISCUSSION: Both histopathologic and immunohistochemical features are consistent with xanthogranuloma. Microscopic features show a granulomatous formation of histiocytes with scattered lymphocytes, touton giant cells, and proliferating vessels. Immunohistochemistry revealed positive expression of CD68 and S100 in histiocytic cells. Adult xanthogranuloma in the central nervous system is exceedingly rare. Association of xanthogranuloma with certain hematologic diseases have been reported, including primary thrombocytopenia and chronic lymphoblastic leukemia.

CONCLUSION: Intracranial xanthogranuloma in adult is rare. Histopathology and immunohistochemistry are paramount in the diagnosis xanthogranuloma. Further screening and continuous monitoring of the patient after surgery is warranted due to possibility of associated hematologic diseases.

KEYWORDS: histopathology, immunohistochemistry, juvenile xanthogranuloma, non-Langerhans-cell histiocytosis
INTRODUCTION: Tumors in the foramen magnum are not uncommon, accounting for 2% of intracranial neoplasms, and the differential diagnosis can be varied. Here we describe a case from a forty-four year old female who complained of one-year history of behavioral, gait, and memory recall changes. Imaging revealed a mass at the Foramen of Monro.

CASE DESCRIPTION: Patient underwent craniotomy and excision of the mass. The specimen was cream-tan, irregular, firm, and with aggregate diameter of 2.2 cm and cream-white cut surfaces. Histomorphologic evaluation showed papillary and gland-like formation, lymphoplasmacytic stroma, and basophilic myxoid areas. Tumor cells showed ovoid nuclei with an abundant eosinophilic cytoplasm. The immunohistochemistry panel revealed immunoreactivity to GFAP, Cam5.2, TTF-1, CD34, patchy staining with CK7, and absence of staining for Synaptophysin, S100, EMA, and Brachyury. A pathologic diagnosis of Chordoid Glioma, CNS WHO Grade 2 was made.

DISCUSSION: The differential diagnoses included papillary glioneuronal tumor (PGNT), metastatic papillary adenocarcinomas, and choroid plexus neoplasm. However, the absence of staining for S100 made the diagnosis of PGNT unlikely. Reactivity to GFAP and absence of EMA staining ruled out metastatic papillary neoplasms, as well as made a choroid plexus neoplasm less likely. Given the absence of staining with brachyury and the staining with TTF-1 and CD34 at the myxoid areas, the diagnosis of a Chordoid Glioma, CNS WHO Grade 2 was finally reached.

CONCLUSION: In patients with masses at the Foramen of Monro, thorough evaluation of the tumor and a comprehensive immunohistochemistry panel to rule out mimickers assists in the pathologic diagnosis of these neoplasms.

KEYWORDS: chordoid, glioma, GFAP
INTRODUCTION: As we are constantly researching ways to induce malignancy reversion, there’s one condition where tumor recurs from malignant to benign.

CASE DESCRIPTION: This is a case of a 21-year-old female who presented with enlarging abdominal mass with increasing ovarian serum tumor markers. Fertility saving was initially the goal however, this proved to be futile. Patient had right ovarian cystectomy (May 2016) revealing a mature teratoma. Another mass was identified and left oophorocystectomy (August 2016) revealed immature teratoma, Grade I, exhibiting ectodermal, mesodermal, and endodermal structures histomorphologically with presence of immature neural components positive with NSE immunohistochemistry. She was subjected to chemotherapy. Patient then developed multiple pelvic implants (June 2020). Absence of immature components is confirmed by its negative NSE. This histomorphology with previous histopathology of immature teratoma and chemotherapy with tumor progression to the pelvis and concomitant normal serum AFP and Ca125 proves a case of Growing Teratoma.

DISCUSSION: GTS is due to tumor transformation from malignant to benign due to “chemotherapeutic retroversion” wherein immature malignant cells are destroyed by chemotherapy, while benign mature cells remain and proliferate into a benign tumor. Diagnostic criteria includes (1) normalization of serum tumor markers, (2) increasing size of lesions on serial imaging with chemotherapy history, (3) exclusive presence of mature teratoma components in resected specimen with known history of malignant immature teratoma.

CONCLUSION: GTS, a rare entity of tumor transformation, is an enigma to this date. Perhaps this is the key to unlocking the cure for malignancy.

KEYWORDS: chemotherapy, ovary, teratoma
A CASE OF HEPATOID ADENOCARCINOMA OF THE COLON WITH METASTASIS TO THE LIVER: A POTENTIAL DIAGNOSTIC CONFUSION IN PATIENTS PRESENTING WITH LIVER MASS

Julienne Ross C. Yarra, MD*, Glenda Lyn Y. Pua, MD
St. Luke's Medical Center, Institute of Pathology, Quezon City, National Capital Region
*jrcyarra@stlukes.com.ph || E. Rodriguez Sr. Ave., Quezon City, 1112 Metro Manila || (02) 87230101, +639088883691

INTRODUCTION: Hepatoid adenocarcinoma (HA) is a rare primary extrahepatic carcinoma described as an α-fetoprotein-producing tumor with histomorphologic findings reminiscent of hepatocellular carcinoma (HCC). HA has been predominantly described in the stomach, but it has also been reported in other organs such as the ovary, esophagus, pancreas, lung, and rarely in the colon.

CASE DESCRIPTION: We report a case of a 53-year-old, male, with liver mass (segments VI and VII), who underwent Posterior Sectionectomy of the liver, and was diagnosed as a case of hepatocellular carcinoma in an outside institution. Postoperative imaging studies revealed sigmoid colonic thickening and multiple ill-defined hypoenhancing lesions in the liver. Subsequent Open Anterior Resection specimens showed moderately-differentiated adenocarcinoma of the sigmoid colon with typical glandular pattern and a solid component with hepatoid features. Excision biopsy of the liver nodule and slide review of the liver specimen showed poorly-differentiated carcinoma with extensive necrosis. Immunohistochemical studies showed positivity for MOC31, CK20, Hep Par-1, Glypican-3 and CDX2 in the hepatoid component and diffuse positivity for MOC31 only in the liver mass specimens. Overall, these support the diagnosis of moderately-differentiated adenocarcinoma, with hepatoid pattern, and with metastasis to the liver.

DISCUSSION: HA of the colon with liver metastasis is a diagnostically-challenging scenario due to its radiologic, histomorphologic and immunophenotypic similarities with HCC. The definitive diagnosis falls heavily on a conscientious search for a primary tumor to avoid misdiagnosis.

CONCLUSION: Hence, in patients presenting with liver mass, metastasis should always be a consideration because a mimic of HCC is likewise a possibility.

KEYWORDS: colon, hepatoid adenocarcinoma
MISSION

To foster solidarity through proactive participation in society activities and advocacies enhanced communication and adherence to professional and ethical standards.

To train highly competent pathologists by providing continuing education and training to our members.

To lead the way towards the advancement in the field of Pathology and Laboratory Medicine through active participation in local and global collaborative research.

To promote the role of socially responsible Pathologists in the healthcare system by coordinating with policy makers, stakeholders, other societies and healthcare partners in service, training and research in the local and international arena in support of the national health agenda.

VISION

The Philippine Society of Pathologists will be a unified and cohesive force composed of highly competent, globally recognized professionals collaborating with local and international health partners, including the academe and other societies working towards the advancement of the profession of Pathology and Laboratory Medicine.

We will be at the forefront of patient care while adhering to the highest standards in service, training and research.
I DO SOLEMNLY SWEAR to adhere to the “Principles of Medical Ethics” of the Philippine Medical Association and to the Code of Ethics of the Philippine Society of Pathologists. Towards this end, I shall devote my services to the greatest benefit of the sick and injured and to ensure the fullest measure of cooperation with my colleagues. I further commit myself to adhere to the following canons of professional ethics:

I SHALL LIMIT my practice to the specialty that I am board-certified in;

I SHALL NOT SOLICIT, directly or indirectly, or any manner whatsoever, or knowingly permit others to solicit in my behalf, nor shall I accept, a position which is occupied or about to be vacated without first consulting with the incumbent or outgoing pathologist;

I SHALL NOT ISSUE a report on preparations or material from another pathologist, or another laboratory or from other institutions which another pathologist serves, without making a reasonable effort to inform that first pathologist of the request for second examination or opinion;

I SHALL NOT DIVIDE, either directly or by means of any subterfuge, fees for laboratory services with referring physicians;

I SHALL NOT COMPETE for professional services on the basis of fees;

I SHALL NOT ISSUE reports to patients except when requested to do so by the patient’s attending physician;

I SHALL NOT PARTICIPATE, directly or by means of any subterfuge, in an arrangement or scheme whereby an individual not duly licensed to practice medicine and not certified nor a member of the society, is allowed to operate a laboratory, clinical or otherwise;

I SHALL NOT ACCEPT a position in any hospital, institution or other medical organization which does not protect the welfare and interest of the pathologist;

I SHALL NOT ALLOW myself to be a willing tool for political purposes nor for the personal interest of others to the prejudice of another pathologist or colleagues in the allied profession;

I SHALL NEVER SPEAK ill of the society or any of my colleagues, nor shall I bring forth any issue before any other forum, administrative or judicial, without first having exhausted all avenues of negotiation or settlement within the society;

I SHALL ALWAYS SHOW RESPECT to the officers of the society as well as to its elders and to the principles that they represent. Towards this end, I shall always exert effort to support the programs and activities of the society and, that further, I shall exert every effort to contribute to the success of its endeavor;

IN WITNESS WHEREOF I have hereunto set my hand and name before God Almighty and before my colleagues in the practice of pathology.
PSP BOARD OF GOVERNORS 2022-2023

Alan T. Koa, MD, FPSP
President

Ma. Cecilia F. Lim, MD, FPSP
Vice President

Jeffrey S. So, MD, FPSP
Secretary

Mirian D. Viterbo, MD, FPSP
Treasurer

Roberto O. Padua, Jr., MD, FPSP
Immediate Past President

Sheldon Steven C. Aquino, MD, FPSP
Member

Herbert G. Pascual, MD, FPSP
Member

Laarnie Cale-Subia, MD, FPSP
Member

Amado O. Tandoc, III, MD, FPSP
Member

Sherjan P. Kalim, MD, FPSP
Member

Rowen T. Yolo, MD, FPSP
Member

John Arnel H. Amata, MD, FPSP
Member
PSP BOARD OF GOVERNORS 2022-2023
PSP BOARD OF PATHOLOGY 2022-2023

Bernadette R. Espiritu, MD, FPSP
Chair

Kalangitan R. Gutierrez, MD, FPSP
Secretary / Treasurer

Debbie Marjorie D. Dela Fuente, MD, FPSP
Member

Estela Marie C. Tanchoco, MD, FPSP
Member

Ma. Bemerly Jardiolin-Sira, MD, FPSP
Member

Emmanuel R. Dela Fuente, MD, FPSP
Member

Marie Christine F. Bernardo, MD, FPSP
Member

Cecilia P. Lepon-Capatoy, MD, FPSP
Member

Edna May Lasap-Go, MD, FPSP
Member

Evette Lilybelle A. Demaisip, MD, FPSP
Member

Baby Lynne C. Asuncion, MD, FPSP
Member
PSP REGIONAL CHAPTERS 2022-2023

Nathanael B. Vidad, MD, FPSP
President / Northern Luzon Chapter

Ma. Theresa T. Enrile, MD, FPSP
President / Central Luzon Chapter

Azeus O. Silva, MD, FPSP
President / Southern Luzon Chapter

Heriberto B. Fornoles, MD, FPSP
President / Bicol Chapter

Bernadette R. Espiritu, MD, FPSP
President / National Capital Region Chapter

Thaddeus C. Hinunangan, MD, DPSP
President / Eastern Visayas Chapter

Kathrina S. Perez, MD, FPSP
President / Central Visayas Chapter

Eriberto R. Layda, MD, FPSP
President / Western Visayas Chapter

Chonilo O. Ruiz, MD, FPSP
President / Northern Mindanao Chapter

Al-Zamzam A. Abubakar, MD, DPSP
President / Southwestern Mindanao Chapter

Noemia D. Bartolome, MD, FPSP
President / Southern Mindanao Chapter
PSP SECRETARIAT 2022-2023

- Michael John G. Arciaga
- Michelle M. Glico
- Ma. Mercedes P. Maleniza
- Jeannette Kirsten Mateo
## PSP List of Accredited Institutions

### 2025

<table>
<thead>
<tr>
<th>No.</th>
<th>Institution</th>
<th>Accreditation Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Cebu Doctors University Hospital</td>
<td>2023-2025</td>
</tr>
<tr>
<td>2</td>
<td>Eastern Visayas Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>3</td>
<td>East Avenue Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>4</td>
<td>Fatima University Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>5</td>
<td>Jose R. Reyes Memorial Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>6</td>
<td>Veterans Memorial Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>7</td>
<td>Quezon City General Hospital</td>
<td>2023-2025</td>
</tr>
<tr>
<td>8</td>
<td>National Kidney and Transplant Institute</td>
<td>2023-2025</td>
</tr>
<tr>
<td>9</td>
<td>Rizal Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>10</td>
<td>Zamboanga Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>11</td>
<td>Saint Louis University Sacred Heart Medical Center</td>
<td>2023-2025</td>
</tr>
<tr>
<td>12</td>
<td>Region I Medical Center</td>
<td>2023-2025</td>
</tr>
</tbody>
</table>

### 2024

<table>
<thead>
<tr>
<th>No.</th>
<th>Institution</th>
<th>Accreditation Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Baguio General Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>2</td>
<td>Batangas Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>3</td>
<td>Cagayan Valley Regional Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>4</td>
<td>Chong Hua Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>5</td>
<td>Dr. Paulino J. Garcia Memorial Research and Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>6</td>
<td>Governor Celestino Gallares Memorial Hospital</td>
<td>2022-2024</td>
</tr>
</tbody>
</table>
# PSP LIST OF ACCREDITED INSTITUTIONS

<table>
<thead>
<tr>
<th>No.</th>
<th>Institution Name</th>
<th>Accreditation Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>Ilocos Training and Regional Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>8</td>
<td>Mariano Marcos Memorial Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>9</td>
<td>MCU-FDTMF Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>10</td>
<td>Northern Mindanao Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>11</td>
<td>Perpetual Succor Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>12</td>
<td>Philippine Childrens Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>13</td>
<td>Southern Phils., Inc. (DMC)</td>
<td>2022-2024</td>
</tr>
<tr>
<td>14</td>
<td>St. Luke's Medical Center - BGC</td>
<td>2022-2024</td>
</tr>
<tr>
<td>15</td>
<td>University of Santo Tomas Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>16</td>
<td>Ospital ng Makati</td>
<td>2022-2024</td>
</tr>
<tr>
<td>17</td>
<td>Corazon Locsin Montelibano Memorial Regional Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>18</td>
<td>Davao Doctors Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>19</td>
<td>FEU-NRMF Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>20</td>
<td>Makati Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>21</td>
<td>Ospital ng Maynila Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>22</td>
<td>Philippine Heart Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>23</td>
<td>Quirino Memorial Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>24</td>
<td>St. Luke's Medical Center Quezon City</td>
<td>2022-2024</td>
</tr>
<tr>
<td>25</td>
<td>The Medical City</td>
<td>2022-2024</td>
</tr>
<tr>
<td>26</td>
<td>UERM Memorial Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>27</td>
<td>UP-PGH Medical Center</td>
<td>2022-2024</td>
</tr>
</tbody>
</table>
# PSP List of Accredited Institutions

<table>
<thead>
<tr>
<th>No.</th>
<th>Institution</th>
<th>Accreditation Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Vicente Sotto Memorial Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>29</td>
<td>Western Visayas Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>30</td>
<td>Jose B. Lingad Memorial Regional Hospital</td>
<td>2022-2024</td>
</tr>
<tr>
<td>31</td>
<td>Valenzuela Medical Center</td>
<td>2022-2024</td>
</tr>
<tr>
<td>32</td>
<td>Chinese General Hospital</td>
<td>2022-2024</td>
</tr>
</tbody>
</table>

## 2023

<table>
<thead>
<tr>
<th>No.</th>
<th>Institution</th>
<th>Accreditation Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>De La Salle University Medical Center</td>
<td>2023</td>
</tr>
<tr>
<td>2</td>
<td>Region II Trauma and Medical Center</td>
<td>2023</td>
</tr>
<tr>
<td>3</td>
<td>Tondo Medical Center</td>
<td>2023</td>
</tr>
<tr>
<td>4</td>
<td>Luna Medical Center</td>
<td>2023</td>
</tr>
<tr>
<td>5</td>
<td>Western Visayas State University and Medical Center</td>
<td>2023</td>
</tr>
<tr>
<td>6</td>
<td>Bataan Medical Center (new)</td>
<td>2023</td>
</tr>
<tr>
<td>7</td>
<td>Angeles University Foundation (new)</td>
<td>2023</td>
</tr>
<tr>
<td>8</td>
<td>Bicol Medical Center (new)</td>
<td>2023</td>
</tr>
<tr>
<td>9</td>
<td>Southern Isabela Medical Center (new)</td>
<td>2023</td>
</tr>
</tbody>
</table>
Highly sensitive, easy-to-use rapid lateral flow test enables quick, accurate identification of HBsAg-positive patients.

- Analytical Sensitivity: 0.1 IU/mL
- Specificity: 99.6%
- Sample Volume: 50 μL
- Read Time: 15 Minutes
- Sample: Whole Blood, Serum And Plasma
- Detect Major Vaccine Escape Mutants

© 2019 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. 120005694-01 09/19
Rhumba Inc.

Delivering Outstanding Value to the Healthcare Industry

ISO 9001:2015 CERTIFIED COMPANY
Lot 5, Blk 1, Tierra Vista Subd., Brgy. 10, Lipa City, Batangas
(043) 233-2586 | www.rhumba-inc.com

GETEIN 1100
Point-of-Care Testing, Immunofluorescence Quantitative Analyzer.

PR-705
Fully automated electrolyte analyzer measures combinations of K, Na, Cl, Ca, and PH.

OUR PARTNERS

- Sysmex
- BD
- Roche
- arkray
- Biomek
- Cornley
- BioBase
- mindray
- DVAB
Mindray CAL 6000 a new generation of cellular analysis line. By combining BC-6000 or BC-6200 auto hematology analyzers and SC-120 Slide Maker & Stainer, CAL 6000 offers flexible configurations which have throughput of up to 220 tests per hour and 120 slides per hour.

The MC-80 is taking digital morphology analysis to the next level, delivering clearer images which are able to capture abnormalities in more detail. With advanced algorithms, the analyzer enables better identification of different cells with high throughput, resulting in greater productivity.

SAL 6000 Chemistry & Immunoassay Integrated System delivers fast throughput and seamless integration of CL-2000i Chemiluminescence Immunoassay System and BS-800 Modular System. In conjunction with the SPL 1000 Sample Processing line, this scalable platform not only provides optimized workflow, it also offers satisfactory operator experience.

Mindray CL-900i

The BS-480/850 Chemistry Analyzer A reliable choice for your emerging laboratory

The BS-600M Chemistry Analyzer Powerful and yet Efficient

The right size for your lab, as one of the world’s smallest, fully automated chemiluminescence immunoassay analyzers, integrates a large capacity and fast assay speed into a compact model, achieving a perfect balance between size and immunoassay testing performance.

BS-240Pro Compact and Robust
touchstar
MEDICAL ENTERPRISES INC.
Confidently committed to quality service
WE OFFER COMPLETE CLINICAL AND MOLECULAR LABORATORY SET UP
About Sansure

SANSURE BIOTECH INC. is a comprehensive solutions provider for in vitro diagnosis with independent innovation gene technology as the core, integrating diagnostic reagents, instruments and independent-clinical laboratory services. SANSURE BIOTECH INC (Stock Code: 688288) was listed on the science and Technology Innovation Board of Shanghai Stock Exchange and listed on the list of China’s top 100 pharmaceutical industry.

160+ Clients in over 160 countries/regions in the world

500+ Over 500 products are CE-marked

200+ Over 200 patents included US approved

10K+ 10,000+ benchmark/first class hospitals and labs

900M+ Revenue of $900M in FY 2022

1B+ 1 billion+ people benefited from Sansure products

iPonatic Portable Molecule Workstation
S-Q36A/S-Q31B (4 Modules)

FEATURES
All-in-one: Extraction, amplification and detection integrated
Easy: Simple operation with pre-packaged kits
Flexible: Test on arrival and on-site
Fast: Nucleic acid lysis within 1 min & results in 8-45 min

APPLICATION SCENARIOS
Medical laboratories, Emergency rooms, Fever clinics, CDCs, Airports, Customs.

Follow “Sansure” on

info@sansure.com.cn
www.sansureglobal.com
Real-time PCR tests for detection of SARS-CoV-2/Flu/RSV, and HPV, and for monitoring of HIV-1 Viral Load

SCAN THE QR CODE TO LEARN MORE

For inquiries, contact sales@macare-medicals.com or +632 8913 4201.
AutoLumo A1860
AUTOMATIC LUMINESCENCE IMMUNOASSAY ANALYZER

**Specification**
- Througput: 180T/h
- Time to 1st Result: 21 mins
- RV Loading Capacity: 80 x 2pcs
- Sample Loading Capacity: 60 samples with 1 STAT channel
- Sample pipette Volume: 8 - 150 μL
- Sample Dilution Factor: up to 2601-fold
- Liquid Level Detection and Clot Detection
- Onboard Reagent Capacity: 25 racks
- Onboard Reagent Storage: independent refrigerating system
- Real-time Residue Calculation (LED Monitor and Software Monitor)
- Consumables Residue Calculation (LED Monitor and Software Monitor)
- Substrate: Substrate A+B
- Substrate Volume: 100 mL for each
- Substrate Switching: 2 sets of substrates available on board by automatic switching
- Carry-over: < 1 ppm
- Reaction mode: 1 step and 2 steps
- Size (WxDxH, mm): 1200 x 736 x 635 mm
- Weight: 183 kg

**Smarter**
- Versatile and strong, brings more accurate results
- Lower Carryover
- Surrounding washing by vacuum brings low carryover, especially beneficial to infectious disease items
- Reduce failure rate
- Stepping work station for magnetic separator, integrated Elution & Injection & Reading & Discard Module
- Lower background
- Bi-directional swimming for washing, decrease non-specific absorption.
- Improve precision
- Innovative vibration mixing, Fully mixed within 1.8s.

**Simpler**
- Easy operation and save time
- Consumable Management
- Visual management of consumables, automatic switch of dual-substrate
- Reagent Management
- Keep cooling after switch off. Random access
- Auto-retesting
- Auto repeat and auto dilution

---

**CLIA MICROPARTICLES**

**Tumor Markers**
- AFP
- CEA
- PSA
- CA125
- CA15-3
- CA19-9
- Ferritin
- β2-Microglobulin
- NSE
- CYFRA 21-1
- SCCA
- CA72-4
- CA19-9
- HE4
- ProGRP
- Pepsinogen I
- Pepsinogen II

**Allergy**
- IgE

**Bone Metabolism**
- Osteocalcin
- Calcitonin
- 25-OH Vitamin D
- PTH

**Infectious Diseases**
- Anti-HCV
- HAV IgM
- HEV IgM
- Anti-HIV
- HIV Ag/Ab Combo
- Anti-TP

**Bone Metabolism**
- Anti-HBV
- Anti-HBs
- Anti-HBe
- Anti-HBc
- HBV PreS1-Ag
- Anti-HBc IgM

**Cardiac Markers**
- NT-proBNP
- BNP
- HS-tTnT

**Hypertension**
- Aldosterone
- ACTH
- Cortisol
- Renin
- Angiotensin II

**Diabetes**
- Insulin C-Peptide

**Thyroid**
- T3
- T4
- TSH
- FT3
- FT4
- Anti-TG
- Anti-TPO
- TG
- PTH
- rt3

**Endocrine Hormone**
- LH
- PSH
- PRL
- Testosterone
- E2
- PRG
- DHEA-S
- SHBG
- Tg-CHP
- AMH

**TORCH**
- Toxo IgM
- CMV IgM
- Rubella IgM
- HSV-1 IgM
- HSV-2 IgM
- Toxo IgG
- CMV IgG
- Rubella IgG
- HSV-1 IgG
- HSV-2 IgG

**Pre-natal**
- Free β-HCG
- P-AFP
- β-HCG
- UE5
- PAPP-A

**Growth Hormone**
- IGF-1
- HGH

**Tuberculosis**
- TB-IGRA

**Inflammation Monitoring**
- hs-CRP
- PCT
- IL-6
- D-dimer
- Anemia
- Vitamin B12
- Folate
- Ferritin

---

**AutoBio**

---

Blue Cross
Where your health matters

1505 State Center Bldg., 333 Juan Luna St., Binondo, Manila

8-687-9999 • 0917-7077777
bluecrosscustomer@euroempire.com
AutoLumo A2000 Plus

AUTOMATIC LUMINESCENCE IMMUNOASSAY ANALYZER

**Specification**
- Throughput: up to 200T/H
- Time to 1st result: approximate 20 mins
- RV loader capacity: 1000 pcs
- Sample loading capacity: 100
- Sample pipette volume: 5-150ul
- STAT available
- Sample dilution factor: 10-100
- Liquid level detection and clot detection
- Onboard reagent capacity: 24 racks
- Onboard reagent storage: 4-10°C
- Real-time replacement of reagent (by appointment)
- Reagent residue calculation: by the rest number left
- Substrate: Substrate A+B
- Substrate Volume: 100ml for each
- Substrate pipetting volume: 50ul fixed, CV<2%
- Substrate switching: 2 sets of substrates available on board by automatic switch
- Carry-over:<1ppm
- Incubation temperature: 37°C ± 0.5°C
- Reaction mode: 1 step and 2 steps
- Size (W*D*H, mm): 1374*950*1200
- Weight: approximate 390kg
- Power supply: AC 100-230V, 50/60Hz, 800VA
- Working temperature: 18-30°C
- LIS communication: based on RS232 port

**Smarter**
- Versatile and strong, brings more accurate results
- Lower Carryover
  - Surrounding washing by vacuum brings low carryover, especially beneficial to infectious disease items.
- Reduce failure rate
  - Stepping work stations for magnetic separation, integrated Elution & Injection & Reading & Discard Module
- Lower background
  - Bi-directional swimming for washing, decreases non-specific absorption
- Improve precision
  - Innovative vibration mixing, fully mixed within 1.8s.

**Simpler**
- Easy operation and save time
- Consumable Management
  - Visual management of consumables, automatic switch of dual-substrate.
- Reagent Management
  - Keep cooling after switch off. Random access.
- Auto-retesting
  - Auto-repeat and auto-dilution.

---

**CLIA MICROPARTICLES**

<table>
<thead>
<tr>
<th>Tumor Markers</th>
<th>Allergy</th>
<th>Thyroid</th>
<th>Diabetes</th>
<th>Endocrine Hormone</th>
<th>TORCH</th>
<th>Growth Hormone</th>
<th>Tuberculosis</th>
<th>Inflammation Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP, CEA, EPO, IPA, CA150, CA19-9, CA125, CA15-3, CA19-9, Ferritin, B2-Microglobulin, NSE, CYFRA 21-1, SCCA, CA72-4, CA242, HE4, ProGRP, Pepsinogen I, Pepsinogen II</td>
<td>IgE</td>
<td>T3, T4, TSH, PTH</td>
<td>Insulin, C-Peptide</td>
<td>LH, FSH, PRL, Testosterone</td>
<td>Toxo IgM, CMV IgM, Rubella IgM, HSV-1 IgG, HSV-2 IgG, Toxo IgG, CMV IgG, Rubella IgG, HSV-1 IgG, HSV-2 IgG</td>
<td>IGF-1, HGH</td>
<td>TB-IgG</td>
<td>hs-CRP, IL-6, D-dimer, Anemia</td>
</tr>
<tr>
<td>Bone Metabolism</td>
<td>Osteocalcin, Calcitonin, 25-OH Vitamin D</td>
<td>PT, TPO, PTH</td>
<td>Hypertension</td>
<td>Angiotensin II</td>
<td>Angiotensin II</td>
<td>Angiotensin II</td>
<td>Angiotensin II</td>
<td>Angiotensin II</td>
</tr>
<tr>
<td>Infectious Diseases</td>
<td>Anti-HCV, HAV IgM, HEV IgM, HEV IgG, Anti-HIV, Anti-HBV, Anti-Hbe, Anti-Hbc</td>
<td>HBV, HBsAg, Anti-HBs, Anti-Hbe, Anti-Hbc</td>
<td>Hepatitis B, C, D, E,</td>
<td>Hepatitis B, C, D, E,</td>
<td>Hepatitis B, C, D, E,</td>
<td>Hepatitis B, C, D, E,</td>
<td>Hepatitis B, C, D, E,</td>
<td>Hepatitis B, C, D, E,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MAGLUMI® X3

Save Your Space without Compromise
Compatible with Small and Medium-sized Hospitals and Labs

- **200** Tests/Hour
- Space occupied < **0.68 m²**
- **72** Sample Positions
- **20** Reagent Positions
- **Single** Reaction Cup

**Small but strong**
The throughput per unit area is 294 T/h/m².
Compatible with all MAGLUMI® reagents with perfect compatibility (183 parameters).

**Convenient and efficient**
No-pause loading/unloading of reagents/samples/reaction cups without waiting or interrupting tests. Intuitive indicator lights make no need to check reagents and consumables frequently.

**Low failure rate and accurate result**
The single reaction cup can avoid light pollution and increase cuvette utilization, its integrated packaging can avoid the stuck of the cuvette, cuvette blockage and scratches.

**Cost-efficient and intelligent**
TEFLON-coated pipetting needle is equipped with independent washing unit to avoid carry-over
(Small workload analyzer have higher consumable costs when using disposable Tips).

**Excellent performance**
The comprehensive advanced design of MAGLUMI® X3 ensures excellent performance, such as the latest intelligent washing technology and bidirectional temperature control measurement.

www.snibe.com | sales@snibe.com
FOCUSED ACROSS SOLUTIONS
BioSystems

The new iPRO

Highly customizable software
- Fits your workflow

Integrated barcode reader
- Faster, better traceability

Higher processing
- 6 racks with 11 samples
- 2 dilution racks with 96 positions
- Easy-handling and adaptable racks for different sample tubes
- Reagents interchangeable

Improved to work more and better in less space
- Making your lab bigger

Compact and cost-effective design
- 775 x 620 x 550 mm
  (width x depth x height)
Gold Standard for Immunology
Chemiluminescence Immunoassay Analyzer

Test Panels

Cardiac Marker
- Myo
- CK-MB
- cTnl
- hs-cTnl
- NT-proBNP
- D-Dimer
- HCY
- Anemia
- Ferritin
- Vitamin B12
- Folate
- Growth
- hGH
- IGF-1
- IGFBP-3

Reproductive Health
- Progesterone
- FSH
- LH
- Testosterone
- AMH
- Inhibin B
- SHBG
- DHEA-S

Liver Health
- CHI3L1
- Allergy
- SAA
- CRP
- HBP
- Total IgE

Thyroid
- TSH
- FT4
- FT3
- T4
- T3
- Tg
- Anti-Tg
- Anti-TPO
- Anti-TSHR

Inflammation
- PCT
- IL-6
- SAA
- CRP
- HBP

Autoimmunity
- ANA
- dsDNA
- Anti-CCP
- RF
- IgG
- IgA
- CTP
- Anti-TPO
- Anti-TSHR

Tumor Marker
- CA 125
- CA 15-3
- CA 19-9
- PSA
- IPBA
- AFP-L3%
- PIVKA-II

Glycometabolism
- C-peptide
- Insulin

MUREX Diagnostic Products Specialists
08 Bonifacio Street, Poblacion East
San Nicolas 2447, Pangasinan 6
119 14th Ave., Cubao, Quezon City, Metro Manila
+63 919 647 158
+075 600 8159
+02 8 962 8748
@ murexdiagnostics.ph
www.murexdiagnostics.com
info@murexdiagnostics.com
A vital leap forward in cardiac testing

Speed meets accuracy where it matters most—the wait is over for hs-cTnI at the point of care.

When ruling out a potential myocardial infarction (MI), every minute spent waiting on test results comes at a cost. Patients and their families are anxious, and clinicians and laboratory professionals are pressured to identify the problem quickly and accurately. Increased time to results adds congestion to an already busy emergency department. But what if ED staff had access to high-sensitivity troponin right at the point of care?

Consider the value of adding a new tool at the clinician’s disposal that can provide high-sensitivity troponin I (hs-cTnI) results in just 8 minutes from a single fingerstick and patient interaction. The solution is intuitive, easily integrates into the existing workflow, and gives laboratory partners centralized control over decentralized testing, so ED throughput can be improved for efficiency and confidence.

The Atellica® VT Li Patient-side Immunoassay Analyzer, powered by Magnotec® Technology, will transform your chest pain assessment process to benefit patients, clinicians, and your operational workflow. Because when it comes to assessing patients with symptoms of an MI in the ED, trust, time, and resources aren’t just valuable—they’re vital.

siemens-healthineers.com/vtli
Simplifying your Diagnostic Needs
COVID-19 Diagnostics | Rapid Tests | RTR | FIA | PCR

Your partner of choice in simple and comprehensive diagnostic solutions
Fast results, easy procedures, flexibility of multiple sample types

Rapid Test Reader (RTR)
FIA System RaFIA & Test Kits

Aridia
Real-Time PCR Tests
Niche range of tropical & respiratory test options!

OnSite
Your partner of choice in simple and comprehensive diagnostic solutions
Fast results, easy procedures, flexibility of multiple sample types

CTK Biotech, Inc. | California, USA | ctkbiotech.com | info@ctkbiotech.com
Digital Pathology Solutions
Innovative solutions empowering laboratories and Pathologists

VENTANA DP 200 slide scanner
Robust, reliable, high-speed scanning with high image quality

VENTANA DP 200 slide scanner features

High-speed scanning: Improved scanning speed at 20x and 40x magnifications

No slide handling: Tray-based slide loading eliminates slide handling errors for improved reliability

High-quality images: Outstanding images for various tissue types, including challenging slides and frozen sections

DICOM compatibility: Provide a standardized output file format for interoperability

Color management: ICC color profile applied to every scanned image

Dynamic focus: Tracks tissue depth in real-time and uses the data for high-resolution images

Quality check: Full screen viewer embedded into Scan Application for streamlined QC of scanned images

© 2023 Roche
VENTANA is a trademark of Roche. All other trademarks are the property of their respective owners

diagnostics.roche.com
This website contains regularly updated information on products which are targeted to a wide range of audiences globally and could contain some products and services which may not be applicable in the Philippines. Please refer any inquiries to your local Roche contact.
Automated Haematology Analyser XN-Series

XN-1500

- Analyser and slide maker
- Streamlined workflow with auto-rerun/reflex capability
- Compact solution for laboratories

www.sysmex.com.ph
An accurate A1c diagnosis required knowing if a hemoglobin variant is present

Quality patient care is at the heart of what you do – and you choose your HbA1c assay accordingly. At Bio-Rad, we share this commitment to excellence and are dedicated to helping you make a difference in patient outcomes by delivering gold standard HPLC technology that gives you the complete patient picture.

Not all HbA1c methods are created equal. HbA1c methods that do not detect hemoglobin variants might lead to misdiagnosis and unnecessary or delayed patient treatment. Whether you’re a small, medium, or large volume laboratory, our family of HbA1c testing solutions provides the complete patient picture so you can aid healthcare providers with making the appropriate diagnosis and initiating the proper treatment protocol.

Bio-Rad is the trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions. All trademarks used herein are the property of their respective owner.

Learn more at [www.bio-rad.com/diagnostics](http://www.bio-rad.com/diagnostics)
HEAD OFFICE
#12 Kaimito Ave. Town and Country Executive Village,
Marcos Hi-way, Mayamot, Antipolo City, Philippines

Contact Numbers
Cellphone: +63 917 121 7000
Landline: (02) 8 477 56 03 | (02) 7 905 4670

Email Address:
sales@biolinemedicalsyste.com
support@biolinemedicalsyste.com

Website:
https://biolinemedicalsyste.com
Drake Marketing and Equipment Corporation

HistoPathology Laboratory Total Solutions:
✓ Innovation
✓ Reliability
✓ Smart
✓ Competitiveness

Cold™ Automatic Cryostat Microtome

Cold™ Biological Safety Pathology Grossing Workstation

Cold™ Automatic Rotary Microtome

Cold™ Spin Tissue Processor (Vacuum)

Cold GmbH
Gewerbestrasse 44431789 Leopoldshoehe
www.coldgmbh.com

Drake Marketing and Equipment Corporation
1052 Benigno Aquino Avenue Sitio 2 Bahay Pare,
Candaba, Pampanga 2013
www.drakephilippines.com
ESCO LIFESCIENCES PROVIDES SOLUTIONS FOR:

- Animal Research Workstations
- Biological Safety Cabinets
- Compounding Isolators
- CO₂ Incubators
- Fume Hoods
- Laminar Flow Cabins
- Laboratory Centrifuge
- Laboratory Ovens and Incubators
- Laboratory Refrigerator and Freezers
- Orbital Shakers
- PCR Thermal Cyclers
- Ultra-Low Temperature Freezers

OUR WIDE RANGE OF QUALITY SERVICES

- Installation and Operational Qualification
- Decontamination
- Repair and Maintenance
- Annual Certification

WHY ENGAGE IN ESCO SERVICES?

- We have an experienced team to resolve equipment issues.
- We have local engineers ready to deploy and provide prompt service.
- We are dedicated to providing advice for equipment care and best practices.
- We have a well-stocked spare parts inventory to reduce waiting time for customers.
- We are a renowned lab equipment manufacturer with a service team trained to follow international testing standards.

Looking for hassle-free services for your laboratory equipment? We got you covered!
Esco Lifesciences gives on-time customer service to meet your needs and keep your equipment in excellent working condition.

Visit www.escolifesciences.com | philippines@escolifesciences.com
GLOBAL • STANDARD • MARKET LEADER
Telephone Number: (02) 880-3522
Cellphone Number: 0932-8516721 / 0917-7148353
Email: info@easy.com.ph
Website: www.easy.com.ph

Your PARTNER in advancing Medical Services through Information Technology
Stronger Together.
From sample preparation and staining to imaging and reporting, we enable you to deliver accurate and timely results for better patient care.

Specimen Preparation
- Consumables
- Specimen ID
- Tissue Processing
- Embedding
- Sectioning

IHC & ISH
- Leica BOND IHC/ISH Instruments
- Novocastra Reagents
- Novocastra HD
- Kreatech FISH Probes

Pathology Imaging
- Aperio ePathology
- Clinical Microscopy
- Cytogenetics

Research
- Neuroscience
- Specimen Preparation
- Routine & Special Staining
- IHC & ISH
- Imaging
- Research Microscopy

Routine & Special Staining
- Consumables
- Routine Stainers & Coverslippers
- Routine Stains
- Special Stains

Workflow
- Leica CEREBRO Specimen Tracking
- Specimen ID

www.mrlcybertec.com
marketing@mrlcybertec.com
facebook.com/mrlcyberteccorp/
POCT IMMUNOLOGY ANALYZER

iCHROMA II  iCHROMA III  AFIAS-3  AFIAS-6

ION-SELECTIVE ELECTRODE TECHNOLOGY  RAPID TEST KITS USING LATERAL FLOW IMMUNOASSAY

MEDICA EasyLyte®  CTK BIOTECH

CLINICAL CHEMISTRY ANALYZER  MICROFLUIDIC COAGULATION ANALYSIS SYSTEM

DiaSys  iHETO

3-PART AUTO HEMATOLOGY ANALYZER & FULL AUTOMATIC DRY BIOCHEMISTRY ANALYZER

seamaty

VITALINE HEALTHCARE INC.
Providing Your Vital Needs
THE ZAFIRE PORTFOLIO

- Laboratory Equipment
- Laboratory Supplies
- Laboratory IT Solutions
- Blood Bank
- Imaging System
- Critical Care
- Perioperative Care
- Wound Care
- Cardiovascular Care
- Hospital Solutions
- Infection Control
- Vet Solutions

www.zafire.com.ph
PROVIDER OF THE BEST QUALITY IMAGING AND LABORATORY EQUIPMENT

- EVIDENT OLYMPUS
  Biological and Research Microscopes
- Sansure
  COVID-19 RT PCR / NAT Testing and Fully Automated Nucleic Acid Extraction
- pathoZoom
  Digital Telepathology
- MetaSystems
  Automated Imaging Solution
- AmoyDx
  Better Life with AmoyDx Therapeutic Fungus Identification Solution
- analytikjena
  Life Sciences: Bioimaging and Thermal Cycler
- Abbott Molecular
  Vysis F.I.S.H Probes
- CLST
  Cryo Storage & Blast Freezer
- Barkey
  Blood Warmers, Dry Plasma Thawer, Pasteurizer
- LMB
  Platelet Agitator/Incubator, Donor Couch, Blood Separator & Robo-sets
- HEMASOFTECH
  We care, Blood Bank Laboratory Information System
- KAWASUMI
  KARMI Blood Bags, Single, Double, Triple, Quadriple & Automatic Plasma Extractor
- METTCH
  LAB TECHNOLOGY
  Centrifuges: Refrigerated Clinical Research Micro-Hematocrit Pipettes
- PHCBi
  formerly Panasonic-SANYO
  Blood Bank, Pharmaceutical Refrigerators, Incubator, Ultra Low Freezers & Autoclaves
- TELSTAR
  Biological Safety Cabinets Class II & Laminar Flow
- GAMMA-SERVICE MEDICAL GmbH
  Gamma Blood Irradiator
- SJ ENG
  Steam Sterilizer Autoclave

WORLD'S MOST TRUSTED BRANDS
Partners for Life
PSP 72ND ANNUAL CONVENTION
ORGANIZING COMMITTEE

OVER-ALL CHAIR  Jeffrey S. So, MD, FPSP
CO-CHAIR        Maria Cecilia F. Lim, MD, FPSP

COMMITTEES

SCIENTIFIC SESSIONS – ANATOMIC PATHOLOGY Jeffrey S. So, MD, FPSP
SCIENTIFIC SESSIONS – CLINICAL PATHOLOGY Ma. Cecilia F. Lim, MD, FPSP
WAYS AND MEANS    Bernadette R. Espiritu, MD, FPSP
INFRASTRUCTURE Rosalie Sabina, Michiko S. Samonte, MD, FPSP
REGISTRATION    Frances Saura Sanchez, MD, FPSP
OPENING CEREMONIES Sierra Roma S. Hernandez, MD, FPSP
CLOSING CEREMONIES Mirian D. Viterbo, MD, FPSP
WELCOME AND FELLOWSHIP NIGHT Francis G. Moria, MD, FPSP
NOMINATION Modesty A. Leano, MD, FPSP
ELECTION        Evette Lilybelle A. Demaisip, MD, FPSP
RESEARCH AND POSTER Justine Alessandra U. Uy, MD, DPSP
AWARDS          Amado O. Tandoc III, MD, FPSP
HOSPITALITY     Jose M. Carnate, Jr., MD, FPSP
SENIOR HOUSE OFFICER Alma N. Aquilizan, MD, FPSP
PUBLICATION     Amado O. Tandoc III, MD, FPSP
MARSHAL         Herbert G. Pascual, MD, FPSP
THE PSP HYMN

Original English Lyrics & Arrangement by: Juanito B. Billote, MD, 1985
Edited & Arranged by: The PSP Executive Officers 2003-04
Score and Melody Adopted from: Ode to Joy, Ludwig van Beethoven, 1824

I.
We’re specialist Pathologists
Lamplight of all specialties
We give the clear-cut truthful seal
Guiding doctors’ hands to heal.
We are right beneath PSP wings,
We care for all within our fold.
Sure we know our feelings blending
Binding hearts to always hold.

Refrain:
God bless Our very own PSP
Bless each one of us, we pray
To be alone may be so precious
It is pain not to belong!

II.
It’s our word that makes it final,
Casting dark of doubts away
Microscopes and analyzers
Make us see beyond the veil.
Some may ask why this could be true,
We say that’s what we’re trained to do:
Searching answers to the mysteries
In man’s blood and troubled flesh.

[Repeat Refrain]

III.
We aid doctors’ diagnosis,
Help the sick and ease their pain;
In labs that patients seldom see
We work with confidentiality.
PSP, our dear society,
We sing our sweet song for you.
Your legacy lives on Forever
Sure as sunrise follows dawn.

[Repeat Refrain]